Crystal form of heterocyclic compound, salt thereof, crystal form of salt thereof, and use

By developing different crystal forms and salt forms of heterocyclic compounds, the problem of lack of suitable salt forms and solid forms in the prior art has been solved, the drug properties and biological activities have been improved, and the drug preparation and application effects have been achieved.

WO2024230672A1PCT designated stage expired Publication Date: 2024-11-14HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/091386
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-23
Filing Date
2024-05-07
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing heterocyclic compounds lack suitable salt type and solid form in drug preparation, which affects their drug properties and biological activity.

Method used

Different crystal forms of heterocyclic compounds and their salt forms, including pharmaceutically acceptable salts and solvates, were developed, and solid forms with excellent application prospects were prepared by a specific molar ratio and combination of solvents.

Benefits of technology

Improves the drug properties and biological activity of heterocyclic compounds, providing better drug preparation conditions and application prospects, especially in the inhibition of 15-PGDH and prevention/treatment related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024091386_14112024_PF_FP_ABST
    Figure CN2024091386_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a crystal form of a heterocyclic compound, a salt thereof, a crystal form of the salt thereof, and a use. Disclosed in the present invention are a pharmaceutically acceptable salt of a heterocyclic compound or a solvate thereof, wherein the heterocyclic compound is a compound represented by formula I-3A and / or a compound represented by formula I-3B. The crystal form of a heterocyclic compound, the salt thereof, and the crystal form of the salt thereof disclosed in the present invention can be used for drug preparation, and have wide application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Crystal form of heterocyclic compound, salt thereof, crystal form of salt thereof and application thereof

[0001] This application claims priority to Chinese Patent Application No. 2023105131520, filed on May 8, 2023. This application claims priority to Chinese Patent Application No. 2024104968301, filed on April 23, 2024. This application incorporates the entire contents of the aforementioned Chinese patent applications. Technical Field

[0002] The present invention belongs to the field of pharmaceutical chemistry, and in particular relates to a crystal form of a heterocyclic compound, a salt thereof, a crystal form of the salt thereof and applications thereof. Background Art

[0003] The 15-hydroxyprostaglandin dehydrogenase (15-PGDH) gene is located on chromosome 4, 4q34-q35, spanning approximately 31kb, with seven exons and a molecular weight of 29kD. 15-PGDH is composed of 266 amino acids and belongs to the short-chain dehydrogenase (SDR) family. It is a dimer composed of two identical subunits, but some believe that it is only enzymatically active when present as a monomer. 15-PGDH is a key enzyme for the degradation and inactivation of prostaglandins (PGs) and related bioactive eicosane substances. It is widely present in normal tissues of humans and mammals, such as the lungs, kidneys, gastrointestinal tract, thyroid, prostate, and placenta. On the one hand, it catalyzes the oxidation of active 15-hydroxyprostaglandins into 15-ketoprostaglandins, whose activity is greatly reduced. On the other hand, it can catalyze the oxidation of NAD + In the presence of coenzyme factors, it degrades some other non-prostaglandin polycyclic aromatic hydrocarbons and reduces carcinogens and pro-carcinogens produced under physiological or pathological conditions through oxidation reactions.

[0004] Chinese invention patent application number 202211449273.5 describes heterocyclic compounds with 15-PGDH inhibitory activity:

[0005] The chemical name of this heterocyclic compound is 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (numbered I-3). The structure contains the following two isomers:

[0006] On the basis of the good biological activity of the compound, it is necessary to develop a suitable salt form and its solid form to obtain improved drugability or other properties.

[0007] Summary of the Invention

[0008] The present invention provides a crystal form of a heterocyclic compound, a salt thereof, a crystal form of the salt thereof, and applications thereof. The salt of the heterocyclic compound provided by the present invention, and the solid form of the heterocyclic compound or its salt can be used for drug preparation and has good application prospects.

[0009] The present invention provides a pharmaceutically acceptable salt of a heterocyclic compound or a solvate thereof (referring to a solvate of a pharmaceutically acceptable salt of a heterocyclic compound).

[0010] The heterocyclic compound is a compound represented by formula I-3A and / or a compound represented by formula I-3B;

[0011] Wherein, the pharmaceutically acceptable salt is a salt formed by a heterocyclic compound and an acid; the acid is selected from hydrochloric acid, phosphoric acid, fumaric acid, tartaric acid, malic acid, ethanedisulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or oxalic acid.

[0012] In one embodiment, in the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the solvent is selected from one or two of isopropyl acetate, acetone, isopropyl alcohol and n-heptane.

[0013] In one embodiment, the heterocyclic compound is a compound represented by Formula I-3A and / or a compound represented by Formula I-3B:

[0014] In one embodiment, when the heterocyclic compound is a compound represented by formula I-3A or a compound represented by formula I-3B, it is a compound represented by formula I-3:

[0015] In one embodiment, the heterocyclic compound is a compound represented by formula I-3B

[0016] In one embodiment, in the pharmaceutically acceptable salt of the heterocyclic compound or a solvate thereof, the molar ratio of the heterocyclic compound to the acid is 1:(0.5-2), for example 1:(0.5-1), or 1:1, 1:0.9 or 1:0.5.

[0017] In one embodiment, in the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the molar ratio of the heterocyclic compound to the solvent is 1:(0.001-2), for example, 1:(0.001-1), or 1:0.05, 1:0.9, 1:0.01, 1:0.04, 1:0.008, 1:0.03, 1:0.3 or 1:0.5.

[0018] In one embodiment, the pharmaceutically acceptable salt or solvate of the heterocyclic compound is:

[0019] A hydrochloride acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of hydrochloric acid, the compound represented by formula I-3B, and acetone is 0.9:1:0.9;

[0020] Or, a phosphate of the compound represented by formula I-3B, wherein the molar ratio of phosphoric acid to the compound represented by formula I-3B is 1:1;

[0021] Or, a phosphate acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of phosphoric acid, the compound represented by formula I-3B, and acetone is 1:1:0.05;

[0022] Or, a fumarate salt of the compound represented by formula I-3B, wherein the molar ratio of fumaric acid to the compound represented by formula I-3B is 1:1;

[0023] Or, L-tartrate of the compound represented by formula I-3B, wherein the molar ratio of tartaric acid to the compound represented by formula I-3B is 1:1;

[0024] Or, L-malate of the compound represented by formula I-3B, wherein the molar ratio of malic acid to the compound represented by formula I-3B is 1:1;

[0025] Or, an isopropanol solvate of an edisulphonate of the compound represented by formula I-3B, wherein the molar ratio of edisulphonic acid, the compound represented by formula I-3B and isopropanol is 0.5:1:0.5;

[0026] Or, an edisylate salt of the compound represented by formula I-3B, wherein the molar ratio of edisylic acid to the compound represented by formula I-3B is 0.5:1;

[0027] Or, an edisylate salt of the compound represented by formula I-3B, wherein the molar ratio of edisylic acid to the compound represented by formula I-3B is 1:1;

[0028] Or, ethanedisulfonic acid salt of the compound represented by formula I-3B and acetone n-heptane solvate, wherein the molar ratio of ethanedisulfonic acid, the compound represented by formula I-3B, acetone and n-heptane is 1:1:0.3:0.03;

[0029] Or, p-toluenesulfonate of the compound represented by formula I-3B, wherein the molar ratio of p-toluenesulfonate to the compound represented by formula I-3B is 1:1;

[0030] Or, a methanesulfonate salt of the compound represented by formula I-3B, wherein the molar ratio of methanesulfonic acid to the compound represented by formula I-3B is 1:1;

[0031] Or, a methanesulfonate n-heptane solvate of the compound represented by formula I-3B, wherein the molar ratio of methanesulfonic acid, the compound represented by formula I-3B, and n-heptane is 1:1:0.008;

[0032] Or, a benzenesulfonate salt of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid to the compound represented by formula I-3B is 1:1;

[0033] or, a benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid, the compound represented by formula I-3B, and isopropanol is 1:1:0.01;

[0034] Or, an oxalate of the compound represented by formula I-3B, wherein the molar ratio of oxalic acid to the compound represented by formula I-3B is 1:1.

[0035] In one embodiment, the solvate of the pharmaceutically acceptable salt of the heterocyclic compound is not the monohydrochloride monohydrate of the heterocyclic compound.

[0036] The present invention provides a crystalline form A of a compound represented by formula I-3B, which has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 18.6±0.2°, and 21.6±0.2°;

[0037] The structure of the compound represented by formula I-3B is:

[0038] In one embodiment, the crystalline form A of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 23.1±0.2°, 17.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2°.

[0039] In one embodiment, the crystalline form A of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 18.6±0.2° and 11.9±0.2°.

[0040] In one embodiment, the crystalline form A of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 23.1±0.2°, 18.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2°.

[0041] In one embodiment, the crystalline form A of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, which has diffraction peaks as shown in Table 1.

[0042] In one embodiment, the crystalline form A of the compound represented by formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG1 .

[0043] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form A of the compound represented by formula I-3B has an endothermic peak starting point at 160.9±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form A of the compound represented by formula I-3B reaches a peak of the endothermic peak at 168.4±3°C.

[0044] In one embodiment, the differential scanning calorimetry (DSC) curve of Form A of the compound represented by Formula I-3B is substantially as shown in FIG2 .

[0045] In one embodiment, the thermogravimetric analysis (TGA) curve of Form A of the compound represented by Formula I-3B shows a weight loss of approximately 0.67% within the temperature range of 14.8±3°C to 120°C±3°C.

[0046] In one embodiment, the thermogravimetric analysis (TGA) curve of Form A of the compound represented by Formula I-3B is substantially as shown in FIG2 .

[0047] In one embodiment, the crystalline form A of the compound represented by formula I-3B is a crystalline form of an isopropyl acetate solvate of the compound represented by formula I-3B, and the molar ratio of the compound represented by formula I-3B to the isopropyl acetate is 1:0.04.

[0048] The present invention provides a crystalline form B of a compound represented by formula I-3B, which has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2° and 14.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0049] In one embodiment, the crystalline form B of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and further has diffraction peaks at one or more of the following positions: 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2°.

[0050] In one embodiment, the crystalline form B of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2° and 19.2±0.2°.

[0051] In one embodiment, the crystalline form B of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2°.

[0052] In one embodiment, the crystalline form B of the compound represented by formula I-3B has a diffraction peak shown in Table 2 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0053] In one embodiment, the crystalline form B of the compound represented by formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG4 .

[0054] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form B of the compound represented by formula I-3B has an endothermic peak starting point at 164.2±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form B of the compound represented by formula I-3B reaches a peak of the endothermic peak at 171.7±3°C.

[0055] In one embodiment, the differential scanning calorimetry (DSC) curve of Form B of the compound represented by Formula I-3B is substantially as shown in FIG5 .

[0056] In one embodiment, the thermogravimetric analysis (TGA) curve of Form B of the compound represented by Formula I-3B shows a weight loss of approximately 1.61% in the temperature range of 26.6±3°C to 120°C±3°C.

[0057] In one embodiment, the thermogravimetric analysis (TGA) curve of Form B of the compound represented by Formula I-3B is substantially as shown in FIG5 .

[0058] The present invention provides a crystalline form of the hydrochloride of the compound represented by formula I-3B, which has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2° and 11.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0059] In one embodiment, in the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to hydrochloric acid is 1:0.9.

[0060] In one embodiment, the crystalline form of the hydrochloride of the compound represented by formula I-3B is a crystalline form of the hydrochloride acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, hydrochloric acid and acetone is 1:0.9:0.9.

[0061] In one embodiment, the crystalline form of the hydrochloride salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2°.

[0062] In one embodiment, the crystalline form of the hydrochloride of the compound represented by formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2° and 20.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0063] In one embodiment, the crystalline form of the hydrochloride of the compound represented by formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2°, 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0064] In one embodiment, the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B has diffraction peaks shown in Table 3 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0065] In one embodiment, the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG7 .

[0066] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B reaches endothermic peaks at 122.1±3°C and 199.6±3°C.

[0067] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B is substantially as shown in FIG8 .

[0068] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B shows a weight loss of approximately 13.39% in the temperature range of 17.7±3°C to 100°C±3°C, and a weight loss of approximately 4.54% in the temperature range of 100±3°C to 150°C±3°C.

[0069] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B is substantially as shown in FIG8 .

[0070] The present invention provides a crystal form of a phosphate of a compound represented by formula I-3B, which has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2° and 11.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0071] In one embodiment, in the crystal form of the phosphate salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to phosphoric acid is 1:1.0.

[0072] In one embodiment, the crystalline form of the phosphate of the compound represented by formula I-3B is a crystalline form of the phosphate acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, phosphoric acid and acetone is 1:1.0:0.05.

[0073] In one embodiment, the crystalline form of the phosphate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2° and 10.2±0.2°.

[0074] In one embodiment, the crystalline form of the phosphate salt of the compound represented by formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2° and 19.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0075] In one embodiment, the crystalline form of the phosphate salt of the compound represented by formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2° and 10.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0076] In one embodiment, the crystal form of the phosphate salt of the compound represented by formula I-3B has diffraction peaks shown in Table 4 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0077] In one embodiment, the crystal form of the phosphate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG9 .

[0078] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the phosphate salt of the compound represented by formula I-3B reaches an endothermic peak at 158.5±3°C.

[0079] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the phosphate salt of the compound represented by formula I-3B is substantially as shown in FIG10 .

[0080] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the phosphate salt of the compound represented by formula I-3B shows a weight loss of approximately 2.07% within the temperature range of 27.4±3°C to 120°C±3°C.

[0081] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystal form of the phosphate salt of the compound represented by formula I-3B is substantially as shown in FIG10 .

[0082] The present invention provides a crystalline form of a fumaric acid complex of a compound represented by formula I-3B, which has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2° and 22.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0083] In one embodiment, in the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to fumaric acid is 1:1.

[0084] In one embodiment, the fumaric acid complex of the compound represented by formula I-3B is a fumaric acid eutectic of the compound represented by formula I-3B.

[0085] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2°.

[0086] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2° and 26.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0087] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0088] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B has diffraction peaks shown in Table 5 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0089] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG11 .

[0090] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B has an endothermic peak starting point at 165.2±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B reaches the peak of the endothermic peak at 167.2±3°C.

[0091] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is substantially as shown in FIG12 .

[0092] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B shows a weight loss of approximately 0.36% within the temperature range of 26.2±3°C to 120°C±3°C.

[0093] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is substantially as shown in FIG12 .

[0094] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is a single crystal of the fumaric acid complex of the compound represented by Formula I-3B, which has the following unit cell parameters: orthorhombic, space group P212121; α=90°, β=90°, γ=90°, The number of asymmetric units in the unit cell is Z = 4, and the crystal density is 1.451 mg / m 3 .

[0095] The present invention provides a crystalline form of L-tartrate of a compound represented by formula I-3B, which has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2° and 23.3±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0096] In one embodiment, in the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to L-tartaric acid is 1:1.

[0097] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2°.

[0098] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2° and 18.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0099] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2°, 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0100] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B has diffraction peaks shown in Table 6 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0101] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG13 .

[0102] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B has an endothermic peak starting point at 162.4±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B reaches a peak of the endothermic peak at 165.7±3°C.

[0103] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B is substantially as shown in FIG14 .

[0104] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B shows a weight loss of approximately 0.57% in the temperature range of 25.9±3°C to 120°C±3°C.

[0105] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B is substantially as shown in FIG14 .

[0106] The present invention provides a crystalline form of a p-toluenesulfonate salt of a compound represented by formula I-3B, which has a diffraction peak at 6.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0107] In one embodiment, in the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to p-toluenesulfonic acid is 1:1.

[0108] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B has a diffraction peak at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2°.

[0109] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2° and 20.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0110] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0111] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B has diffraction peaks shown in Table 7 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0112] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 15 .

[0113] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B reaches an endothermic peak at 278.9±3°C.

[0114] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B is shown in FIG16 .

[0115] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B shows a weight loss of approximately 0.89% within the temperature range of 25.9±3°C to 150°C±3°C.

[0116] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B is shown in FIG16 .

[0117] The present invention provides a crystalline form of L-malate of a compound represented by formula I-3B, which has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2° and 22.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0118] In one embodiment, in the crystalline form of the L-malate salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to L-malic acid is 1:1.

[0119] In one embodiment, the crystalline form of the L-malate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2°.

[0120] In one embodiment, the crystalline form of the L-malate salt of the compound represented by formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2° and 17.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0121] In one embodiment, the crystalline form of the L-malate salt of the compound represented by formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0122] In one embodiment, the crystalline form of the L-malate salt of the compound represented by Formula I-3B has diffraction peaks shown in Table 8 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0123] In one embodiment, the crystalline form of the L-malate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 17 .

[0124] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-malate salt of the compound represented by formula I-3B has an endothermic peak starting point at 120.4±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the L-malate salt of the compound represented by formula I-3B reaches endothermic peaks at 128.1±3°C and 213.6±3°C.

[0125] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B is substantially as shown in FIG18 .

[0126] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B shows a weight loss of approximately 1.31% within the temperature range of 27.5±3°C to 100°C±3°C.

[0127] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B is substantially as shown in FIG18 .

[0128] The present invention provides a crystalline form A of an edisylate salt of a compound represented by formula I-3B, which has diffraction peaks at 5.3±0.2° and 18.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0129] In one embodiment, in the crystalline form A of the edisylate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to edisylic acid is 1:0.5.

[0130] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B is a crystalline form of the edisylate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, edisylic acid and isopropanol is 1:0.5:0.5.

[0131] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2°.

[0132] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B has diffraction peaks at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2° and 21.6±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0133] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2°.

[0134] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B has the diffraction peaks shown in Table 9 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0135] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 19 .

[0136] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B reaches the peak values ​​of the endothermic peaks at 162.8±3°C and 239.7±3°C, and reaches the peak value of the exothermic peak at 198.8±3°C.

[0137] In one embodiment, the differential scanning calorimetry (DSC) curve of Form A of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG. 20 .

[0138] In one embodiment, the thermogravimetric analysis (TGA) curve of Form A of the edisylate salt of the compound represented by Formula I-3B shows a weight loss of approximately 9.08% within the temperature range of 25.2±3°C to 170°C±3°C.

[0139] In one embodiment, the thermogravimetric analysis (TGA) curve of Form A of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG20 .

[0140] The present invention provides a crystalline form B of an edisylate salt of a compound represented by formula I-3B, which has diffraction peaks at 18.6±0.2°, 19.4±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0141] In one embodiment, in the crystalline form B of the edisylate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to edisylic acid is 1:0.5.

[0142] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2°.

[0143] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2° and 15.1±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0144] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2°.

[0145] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by formula I-3B has the diffraction peaks shown in Table 10 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0146] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 21 .

[0147] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B has an endothermic peak starting point at 235.8±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B reaches an endothermic peak at 242.4±3°C.

[0148] In one embodiment, the differential scanning calorimetry (DSC) curve of Form B of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG. 22 .

[0149] In one embodiment, the thermogravimetric analysis (TGA) curve of Form B of the edisylate salt of the compound represented by Formula I-3B shows a weight loss of approximately 1.84% in the temperature range of 28.4±3°C to 150°C±3°C.

[0150] In one embodiment, the thermogravimetric analysis (TGA) curve of Form B of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG22 .

[0151] The present invention provides a crystalline form C of an edisylate salt of a compound represented by formula I-3B, which has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2° and 23.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0152] In one embodiment, in the crystalline form C of the edisylate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to edisylic acid is 1:1.

[0153] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B is a crystalline form of the edisylate salt of the compound represented by formula I-3B acetone n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, edisylic acid, acetone and n-heptane is 1:1:03:0.03.

[0154] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 7.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2°.

[0155] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2° and 17.3±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0156] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2°, 17.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2°.

[0157] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B has the diffraction peaks shown in Table 11 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0158] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 23 .

[0159] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B reaches endothermic peaks at 109.5±3°C and 243.6±3°C.

[0160] In one embodiment, the differential scanning calorimetry (DSC) curve of Form C of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG. 24 .

[0161] In one embodiment, the thermogravimetric analysis (TGA) curve of Form C of the edisylate salt of the compound represented by Formula I-3B shows a weight loss of approximately 7.28% within the temperature range of 28.6±3°C to 150°C±3°C.

[0162] In one embodiment, the thermogravimetric analysis (TGA) curve of Form C of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG. 24 .

[0163] The present invention provides a crystalline form of a mesylate salt of a compound represented by formula I-3B, which has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2° and 21.8±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0164] In one embodiment, in the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to methanesulfonic acid is 1:1.

[0165] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B is a crystalline form of the methanesulfonate salt of the compound represented by formula I-3B in n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, methanesulfonic acid and n-heptane is 1:1:0.008.

[0166] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2°.

[0167] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2° and 15.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0168] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0169] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B has diffraction peaks shown in Table 12 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0170] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 25 .

[0171] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B has an endothermic peak starting point at 116.3±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B reaches a peak endothermic peak at 124.3±3°C.

[0172] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG26 .

[0173] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B shows a weight loss of approximately 4.53% within the temperature range of 28.4±3°C to 80°C±3°C.

[0174] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG26 .

[0175] The present invention provides a crystalline form of a benzenesulfonate salt of a compound represented by formula I-3B, which has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2° and 21.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0176] In one embodiment, in the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to benzenesulfonic acid is 1:1.

[0177] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B is a crystalline form of the benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, benzenesulfonic acid and isopropanol is 1:1:0.01.

[0178] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2°.

[0179] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, and 19.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0180] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0181] In one embodiment, the benzenesulfonate salt of the compound represented by Formula I-3B has diffraction peaks shown in Table 13 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0182] In one embodiment, the benzenesulfonate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 27 .

[0183] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B reaches the peak of the endothermic peak at 254.1±3°C.

[0184] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG28 .

[0185] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B shows a weight loss of approximately 1.32% within the temperature range of 28.4±3°C to 150°C±3°C.

[0186] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG28 .

[0187] The present invention provides a crystalline form of an oxalate salt of a compound represented by formula I-3B, which has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2° and 16.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0188] In one embodiment, in the crystalline form of the oxalate salt of the compound represented by Formula I-3B, the molar ratio of the compound represented by Formula I-3B to oxalic acid is 1:1.

[0189] In one embodiment, the crystalline form of the oxalate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 19.2±0.2°, 15.4±0.2°, 23.6±0.2° and 22.4±0.2°.

[0190] In one embodiment, the crystalline form of the oxalate salt of the compound represented by formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2° and 15.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0191] In one embodiment, the crystalline form of the oxalate salt of the compound represented by formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2°, 15.4±0.2°, 23.6±0.2°, 22.4±0.2° and 28.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0192] In one embodiment, the crystalline form of the oxalate salt of the compound represented by Formula I-3B has diffraction peaks shown in Table 14 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0193] In one embodiment, the crystalline form of the oxalate salt of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as shown in FIG. 29 .

[0194] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the oxalate salt of the compound represented by formula I-3B reaches endothermic peaks at 129.7±3°C and 198.2±3°C.

[0195] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B is substantially as shown in FIG30 .

[0196] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B shows a weight loss of approximately 2.27% within the temperature range of 28.4±3°C to 100°C±3°C.

[0197] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B is substantially as shown in FIG30 .

[0198] The present invention provides a method for preparing a crystalline form of the compound represented by the above formula I-3B, which comprises the following steps:

[0199] crystallizing the mixture of the compound represented by Formula I-3B and the solution to obtain a crystalline form of the compound represented by Formula I-3B or a solvate thereof;

[0200] Wherein, when the crystalline form A of the compound represented by formula I-3B is obtained, the solvent is isopropyl acetate;

[0201] When the crystalline form B of the compound represented by formula I-3B is obtained, the solvent is one or more of methanol, water, acetonitrile and methyl tert-butyl ether.

[0202] In one embodiment, in the method for preparing the crystalline form of the compound represented by Formula I-3B, when the crystalline form A of the compound represented by Formula I-3B is obtained, the crystallization is performed by cooling the mixture of isopropyl acetate and the compound represented by Formula I-3B to room temperature and drying (e.g., volatilizing) to obtain the crystalline form A of the compound represented by Formula I-3B.

[0203] In one embodiment, in the method for preparing the crystalline form of the compound represented by formula I-3B, when the crystalline form B of the compound represented by formula I-3B is obtained, the solvent is a mixed solution of methanol and water or a mixed solution of acetonitrile and methyl tert-butyl ether, preferably a mixed solution of methanol and water with a volume ratio of methanol to water of 1:5.

[0204] In one embodiment, in the method for preparing the crystalline form of the compound represented by formula I-3B, when the crystalline form B of the compound represented by formula I-3B is obtained, the crystallization is performed by crystallizing a mixture of the compound represented by formula I-3B and methanol and water (for example, a mixed solution of methanol and water with a volume ratio of 1:5) at 50°C (for example, stirring at 50°C for 3 days), and drying (for example, drying at room temperature) to obtain the crystalline form B of the compound represented by formula I-3B.

[0205] The present invention provides a method for preparing the above-mentioned crystal form, which comprises the following steps:

[0206] crystallizing a mixture of the compound represented by formula I-3B, an acid, and a solvent;

[0207] Wherein, when the crystalline form of the hydrochloride salt of the compound represented by formula I-3B is obtained, the acid is hydrochloric acid and the solvent is acetone;

[0208] When the crystalline form of the phosphate of the compound represented by formula I-3B is obtained, the acid is phosphoric acid, and the solvent is a mixed solution of acetone and n-heptane;

[0209] When the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is obtained, the acid is fumaric acid, and the solvent is a mixed solution of acetone and n-heptane;

[0210] When the crystalline form of L-tartrate of the compound represented by formula I-3B is obtained, the acid is tartaric acid, and the solvent is a mixed solution of acetone and n-heptane;

[0211] When the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B is obtained, the acid is p-toluenesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0212] When the crystalline form of L-malate of the compound represented by formula I-3B is obtained, the acid is malic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0213] When the crystalline form A of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropanol;

[0214] When the crystalline form B of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropyl acetate;

[0215] When the crystalline form C of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0216] When the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B is obtained, the acid is methanesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0217] When the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B is obtained, the acid is benzenesulfonic acid and the solvent is isopropanol;

[0218] When the crystalline form of the oxalate salt of the compound represented by formula I-3B is obtained, the acid is oxalic acid, and the solvent is a mixed solution of acetone and n-heptane.

[0219] In one embodiment, in the preparation method, when the solvent is a mixed solution of acetone and n-heptane, the volume ratio of the acetone to n-heptane is 1:1.

[0220] In one embodiment, in the preparation method, the molar ratio of the compound represented by formula I-3B to the acid is conventional in the art, for example, the molar ratio of the heterocyclic compound to the acid is 1:1.

[0221] In one embodiment, the preparation method comprises the following steps: suspending (e.g., suspending and stirring) the compound represented by formula I-3B, an acid, and a solvent to obtain a mixture, and crystallizing to obtain a crystalline form.

[0222] In a certain embodiment, in the preparation method, when the obtained crystal form is the hydrochloride salt of the compound represented by Formula I-3B, the L-malate salt of the compound represented by Formula I-3B, the crystalline form B of the edisylate salt of the compound represented by Formula I-3B, the crystalline form C of the edisylate salt of the compound represented by Formula I-3B, the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B, or the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B, the crystallization comprises the following steps: subjecting the mixture of the compound represented by Formula I-3B, the acid and the solvent to temperature cycling (for example, in the range of 50°C-5°C, with a heating rate of 4.5°C / min and a cooling rate of 0.1°C / min, and maintaining a constant temperature at 50°C or 5°C for 2 hours for heating and cooling cycles), and drying (for example, vacuum drying at room temperature).

[0223] In a certain embodiment, in the preparation method, when the crystal form of the phosphate salt of the compound shown in Formula I-3B, the crystal form of the fumaric acid complex of the compound shown in Formula I-3B, the crystal form of the L-tartrate of the compound shown in Formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in Formula I-3B, the crystal form A of the edisylate of the compound shown in Formula I-3B, or the crystal form of the oxalate of the compound shown in Formula I-3B is obtained, the crystallization comprises the following steps: drying the mixture of the compound shown in Formula I-3B, the acid and the solvent (for example, vacuum drying at room temperature).

[0224] The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable salt of the above-mentioned heterocyclic compound or a solvate thereof (referring to a solvate of a pharmaceutically acceptable salt of the heterocyclic compound), and a pharmaceutically acceptable carrier.

[0225] The present invention provides a pharmaceutical composition, comprising a substance X and a pharmaceutically acceptable carrier, wherein the substance X is the crystalline form A of the compound represented by Formula I-3B, the crystalline form B of the compound represented by Formula I-3B, the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B, the crystalline form of the phosphate salt of the compound represented by Formula I-3B, the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B, the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B, the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B, the crystalline form of the L-malate salt of the compound represented by Formula I-3B, the crystalline form A of the edisylate salt of the compound represented by Formula I-3B, the crystalline form B of the edisylate salt of the compound represented by Formula I-3B, the crystalline form C of the edisylate salt of the compound represented by Formula I-3B, the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B, the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B, or the crystalline form of the oxalate salt of the compound represented by Formula I-3B.

[0226] In the pharmaceutical composition, the crystal form of the fumaric acid complex of the compound represented by Formula I-3B may be a single crystal of the fumaric acid complex of the compound represented by Formula I-3B.

[0227] The present invention provides a pharmaceutically acceptable salt or solvate of the above-mentioned heterocyclic compound (referring to a solvate of a pharmaceutically acceptable salt of a heterocyclic compound), the above-mentioned pharmaceutical composition or the use of substance X;

[0228] The substance X is the crystalline form A of the compound represented by formula I-3B, the crystalline form B of the compound represented by formula I-3B, the crystalline form of the hydrochloride salt of the compound represented by formula I-3B, the crystalline form of the phosphate salt of the compound represented by formula I-3B, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B, the crystalline form of the L-tartrate salt of the compound represented by formula I-3B, the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B, the crystalline form of the L-malate salt of the compound represented by formula I-3B, the crystalline form A of the edisylate salt of the compound represented by formula I-3B, the crystalline form B of the edisylate salt of the compound represented by formula I-3B, the crystalline form C of the edisylate salt of the compound represented by formula I-3B, the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B, or the crystalline form of the oxalate salt of the compound represented by formula I-3B;

[0229] The applications include: inhibiting 15-PGDH; and / or preventing and / or treating diseases related to 15-PGDH; and / or preparing 15-PGDH inhibitors, and / or preparing drugs, pharmaceutical compositions or preparations for preventing and / or treating diseases related to 15-PGDH.

[0230] Preferably, the 15-PGDH-related diseases include, but are not limited to, one, two or more of: fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft-versus-host disease, hair growth, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstruction, tissue damage, cervical disease and kidney disease.

[0231] Preferably, the 15-PGDH-related diseases include, but are not limited to, one, two or more of: fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft-versus-host disease, hair growth, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstruction, tissue damage, cervical disease and kidney disease. Preferably, the 15-PGDH-related diseases include but are not limited to: fibrotic diseases (such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, etc., liver fibrosis, renal fibrosis, myocardial fibrosis, scleroderma and myelofibrosis), inflammatory diseases [such as chronic obstructive pulmonary disease (COPD), acute lung injury, sepsis, asthma and exacerbation of lung disease, inflammatory bowel disease (IBD) (such as ulcerative colitis and Crohn's disease), peptic ulcer (such as NSAID-induced ulcer), autoinflammatory diseases (such as Behcet's disease), vasculitis syndrome, acute liver injury, acute kidney injury, non-alcoholic fatty liver disease (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndrome (such as chronic prostatitis / chronic pelvic pain syndrome)], cardiovascular diseases (such as pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, stroke and peripheral circulatory disorders), renal disease (such as chronic kidney disease and renal failure), trauma (such as diabetic ulcer, burns, etc.), and prostatitis syndrome. The invention also includes one, two or more of the following: trauma, pressure ulcers, acute mucosal injury, including Stevens-Johnson syndrome, mucosal injury (such as mucositis or stomatitis), injury associated with anticancer chemotherapeutic agents (anticancer chemotherapeutic agents mainly such as alkylating agents, DNA synthesis inhibitors, DNA gyrase inhibitors) or antimetabolites, cellular or humoral immunotherapy or radiation-related injury), autoimmune diseases (such as multiple sclerosis or rheumatoid arthritis), graft-versus-host disease (GVHD), hair growth, osteoporosis, ear diseases (such as hearing loss, tinnitus, vertigo and balance disorders), eye diseases (such as glaucoma and dry eyes), neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death (such as psychiatric neurological diseases, neuropathies, neurotoxic diseases, neuropathic pain and neurodegenerative diseases), liver regeneration, muscle regeneration (such as muscle atrophy, muscular dystrophy and muscle injury) and cervical disease.

[0232] Preferably, the tissue damage is liver damage and / or muscle damage (such as muscle atrophy and muscular dystrophy).

[0233] Preferably, the 15-PGDH-related diseases include but are not limited to idiopathic pulmonary fibrosis (IPF).

[0234] Preferably, the prevention and / or treatment of 15-PGDH-related diseases includes but is not limited to: liver regeneration.

[0235] Preferably, the 15-PGDH-related diseases include but are not limited to liver damage.

[0236] Preferably, the 15-PGDH-related diseases include but are not limited to inflammatory bowel disease (IBD).

[0237] The present invention provides a use of a pharmaceutically acceptable salt or solvate thereof (referring to a solvate of a pharmaceutically acceptable salt of a heterocyclic compound), a pharmaceutical composition, or a substance X, wherein the use is for preventing and / or treating the following diseases, and / or the use is for preparing a medicament for preventing or treating the following diseases; the diseases are one or more of fibrotic diseases, inflammatory diseases, or tissue damage;

[0238] The substance X is the crystalline form A of the compound represented by formula I-3B, the crystalline form B of the compound represented by formula I-3B, the crystalline form of the hydrochloride salt of the compound represented by formula I-3B, the crystalline form of the phosphate salt of the compound represented by formula I-3B, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B, the crystalline form of the L-tartrate salt of the compound represented by formula I-3B, the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B, the crystalline form of the L-malate salt of the compound represented by formula I-3B, the crystalline form A of the edisylate salt of the compound represented by formula I-3B, the crystalline form B of the edisylate salt of the compound represented by formula I-3B, the crystalline form C of the edisylate salt of the compound represented by formula I-3B, the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B, or the crystalline form of the oxalate salt of the compound represented by formula I-3B;

[0239] The fibrotic disease, the inflammatory disease and the tissue damage may all be the same as described above.

[0240] In the application, the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B may be a single crystal of the fumaric acid complex of the compound represented by Formula I-3B.

[0241] Explanation of terms:

[0242] Unless otherwise specified, the definitions of groups and terms in this specification and claims, including definitions as examples, exemplary definitions, preferred definitions, definitions in tables, and definitions of specific compounds in the examples, may be arbitrarily combined and coupled with each other. The definitions and compound structures obtained by such combinations and couplings shall fall within the scope of the description of this specification. Unless otherwise specified, the terms used in this invention have the following meanings:

[0243] The term "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant governmental regulatory authorities as acceptable for human or veterinary use.

[0244] The term "treat" refers to therapeutic treatment. When referring to a specific condition, treatment means: (1) alleviating the disease or one or more biological manifestations of the condition, (2) interfering with (a) one or more points in the biological cascade that leads to or causes the condition or (b) one or more biological manifestations of the condition, (3) ameliorating one or more symptoms, effects, or side effects associated with the condition or one or more symptoms, effects, or side effects associated with the condition or its treatment, or (4) slowing the progression of the condition or one or more biological manifestations of the condition.

[0245] The term "prevent" refers to the reduction of the risk of acquiring or developing a disease or disorder.

[0246] The term "inflammatory bowel disease," or IBD, is used to describe conditions involving chronic inflammation of the digestive tract. The main types include ulcerative colitis and Crohn's disease. Ulcerative colitis causes inflammation and ulcers in the superficial lining of the large intestine (colon) and rectum. Crohn's disease, on the other hand, is characterized by inflammation of the digestive tract lining, often affecting deeper layers.

[0247] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.

[0248] The reagents and raw materials used in the present invention are commercially available.

[0249] The positive progress of the present invention is that the crystal form of the heterocyclic compound, the pharmaceutically acceptable salt of the heterocyclic compound or the solvate thereof provided by the present invention has good effects and is easy to prepare into medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0250] FIG1 is an X-ray powder diffraction pattern of Form A of the compound represented by Formula I-3B.

[0251] FIG2 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of Form A of the compound represented by Formula I-3B.

[0252] FIG3 is a temperature-variable XRPD pattern of Form A of the compound represented by Formula I-3B.

[0253] FIG4 is an X-ray powder diffraction pattern of Form B of the compound represented by Formula I-3B.

[0254] FIG5 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of Form B of the compound represented by Formula I-3B.

[0255] FIG6 is a temperature-variable XRPD pattern of Form B of the compound represented by Formula I-3B.

[0256] FIG7 is an X-ray powder diffraction pattern of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B.

[0257] FIG8 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B.

[0258] FIG9 is an X-ray powder diffraction pattern of the crystalline form of the phosphate salt of the compound represented by Formula I-3B.

[0259] FIG10 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of the crystal form of the phosphate salt of the compound represented by Formula I-3B.

[0260] FIG11 is an X-ray powder diffraction pattern of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B.

[0261] FIG12 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B.

[0262] FIG13 is an X-ray powder diffraction pattern of the crystalline form of L-tartrate salt of the compound represented by Formula I-3B.

[0263] FIG14 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B.

[0264] FIG15 is an X-ray powder diffraction pattern of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B.

[0265] FIG16 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B.

[0266] FIG17 is an X-ray powder diffraction pattern of the crystalline form of the L-malate salt of the compound represented by Formula I-3B.

[0267] FIG18 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B.

[0268] FIG19 is an X-ray powder diffraction pattern of Form A of the edisylate salt of the compound represented by Formula I-3B.

[0269] FIG20 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of Form A of the edisylate salt of the compound represented by Formula I-3B.

[0270] FIG21 is an X-ray powder diffraction pattern of Form B of the edisylate salt of the compound represented by Formula I-3B.

[0271] FIG22 shows the differential scanning calorimetry curve and thermogravimetric analysis curve of Form B of the edisylate salt of the compound represented by Formula I-3B.

[0272] FIG23 is an X-ray powder diffraction pattern of Form C of the edisylate salt of the compound represented by Formula I-3B.

[0273] FIG24 shows the differential scanning calorimetry curve and thermogravimetric analysis curve of Form C of the edisylate salt of the compound represented by Formula I-3B.

[0274] FIG25 is an X-ray powder diffraction pattern of the crystalline form of the mesylate salt of the compound represented by Formula I-3B.

[0275] FIG26 shows the differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B.

[0276] FIG27 is an X-ray powder diffraction pattern of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B.

[0277] FIG28 shows the differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B.

[0278] FIG29 is an X-ray powder diffraction pattern of the crystalline form of the oxalate salt of the compound represented by Formula I-3B.

[0279] FIG30 is a differential scanning calorimetry curve and a thermogravimetric analysis curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B.

[0280] Figure 31 is a diagram of the single crystal structure of compound R1.

[0281] FIG32 is an XRPD pattern of the dynamic solubility of the compound represented by Formula I-3B in H2O.

[0282] FIG33 is an XRPD pattern of the dynamic solubility of the compound represented by Formula I-3B in SGF.

[0283] Figure 34 is an XRPD pattern of the dynamic solubility of the compound represented by Formula I-3B in FaSSIF.

[0284] Figure 35 is an XRPD pattern of the dynamic solubility of the compound represented by Formula I-3B in FeSSIF.

[0285] FIG36 is an XRPD pattern of the dynamic solubility of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B in H2O.

[0286] FIG37 is an XRPD diagram of the dynamic solubility of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B in SGF.

[0287] FIG38 is an XRPD pattern of the dynamic solubility of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B in FaSSIF.

[0288] FIG39 is an XRPD diagram of the dynamic solubility of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B in FeSSIF.

[0289] FIG40 is an XRPD pattern of the stability evaluation of Form A of the compound represented by Formula I-3B.

[0290] FIG41 is an XRPD pattern of the stability evaluation of Form B of the compound represented by Formula I-3B.

[0291] FIG42 is an XRPD pattern of the crystalline stability evaluation of the fumaric acid complex of the compound represented by Formula I-3B.

[0292] FIG43 is an XRPD pattern of the crystalline stability evaluation of the L-tartrate salt of the compound represented by Formula I-3B.

[0293] Figure 44 is an XRPD pattern of Form A of the compound represented by Formula I-3B before and after the hygroscopicity test.

[0294] Figure 45 is an XRPD pattern of Form B of the compound represented by Formula I-3B before and after the hygroscopicity test.

[0295] FIG46 is an XRPD pattern of the crystal form of the fumaric acid complex of the compound represented by Formula I-3B before and after the hygroscopicity test.

[0296] Figure 47 is an XRPD pattern of the crystal form of the L-tartrate salt of the compound represented by Formula I-3B before and after the hygroscopicity test.

[0297] FIG48 is a comparison of the XRPD pattern of the crystal fitting of the fumaric acid complex of the compound shown in I-3B and the measured XRPD pattern.

[0298] FIG49 is an ellipsoid diagram of the molecular structure of the fumaric acid complex crystal of the compound shown in I-3B. DETAILED DESCRIPTION

[0299] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.

[0300] Symbol or unit:

[0301] IC 50 : Half-maximal inhibitory concentration, which refers to the concentration at which half of the maximum inhibitory effect is achieved

[0302] M: mol / L, for example, n-butyllithium (14.56 mL, 29.1 mmol, 2.5 M n-hexane solution) means a n-butyllithium n-hexane solution with a molar concentration of 2.5 mol / L

[0303] N: equivalent concentration, for example, 2N hydrochloric acid means 2 mol / L hydrochloric acid solution

[0304] Reagents:

[0305] Comparison table of Chinese and English names of solvents selected in the examples

[0306] Crystal form detection instruments and methods:

[0307] 1. X-ray powder diffraction (XRPD)

[0308] The XRPD pattern was collected on an X-ray powder diffraction analyzer produced by PANalytacal. The scanning parameters are shown in the following table:

[0309] 2. X-ray single crystal diffraction

[0310] Test environment: test temperature: 200(2)K, room temperature: 24°C, relative humidity: 34%, X-ray single crystal diffraction method is as follows:

[0311] 3. Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC)

[0312] TGA and DSC images were collected on a TA 5500 thermogravimetric analyzer and a TA 2500 differential scanning calorimeter, respectively. The following table lists the test parameters:

[0313] 4. Solution NMR:

[0314] Liquid-state NMR spectra were collected on a Bruker 400M NMR spectrometer using DMSO-d6 as the solvent.

[0315] 5. High Performance Liquid Chromatography (HPLC):

[0316] In the experiment, the purity test, dynamic solubility and stability test were completed by UPLC ultra-high performance liquid chromatography. The analysis conditions are shown in the following table:

[0317] 6. Dynamic moisture sorption (DVS):

[0318] Dynamic moisture sorption (DVS) curves were collected on a DVS Intrinsic Plus instrument from SMS (Surface Measurement Systems). Relative humidity at 25°C was calibrated using the deliquescent points of LiCl, Mg(NO3)2, and KCl. The DVS test parameters are listed in the table below:

[0319] 7. Ion Chromatography (IC):

[0320] The instrument parameters for determining the molar ratio of counter ions by ion chromatography (IC) are listed in the analytical conditions as shown in the following table:

[0321] Example 1 Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one

[0322] The synthetic route of the target compound is as follows:

[0323] Step 1: 4-Bromo-2-hydrazinopyridine (B3-2)

[0324] 80% hydrazine hydrate solution (17 mL) was added to a solution of 4-bromo-2-fluoropyridine (5 g, 28.4 mmol) in ethanol (50 mL). The reaction mixture was stirred at room temperature for 12 h and concentrated. The residue was diluted with water (50 mL) and extracted with ethyl acetate (50 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and dried to give 4-bromo-2-hydrazinopyridine (3.7 g, yield 69.3%).

[0325] LC-MS, M / Z(ESI):187.9[M+H] + .

[0326] Step 2: 7-Bromo-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (B3-3)

[0327] 4-Bromo-2-hydrazinopyridine (3.2 g, 17.02 mmol) was dissolved in tetrahydrofuran (30 mL), and carbonyldiimidazole (5.52 g, 34.0 mmol) was added. The mixture was stirred at room temperature for 12 h, diluted with water (50 mL), and extracted with ethyl acetate (50 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and dried, and slurried with ethyl acetate (10 mL) to give 7-bromo-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (2.2 g, yield 60.4%).

[0328] LC-MS, M / Z(ESI):213.9[M+H] + .

[0329] Step 3: 7-Bromo-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (B3-4)

[0330] To a mixture of 7-bromo-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (500 mg, 2.33 mmol) and cesium carbonate (1.14 g, 3.50 mmol) in DMF (5 mL) was added iodomethane (995 mg, 7.01 mmol) dropwise at room temperature. The mixture was stirred at room temperature for 3 h, diluted with water (20 mL), and extracted with ethyl acetate (20 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried. The crude product was separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 5:1-1:1) to give 7-bromo-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (400 mg, yield 75%).

[0331] LC-MS, M / Z(ESI):227.9[M+H] + .

[0332] Step 4: 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one

[0333] Under nitrogen protection, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridin-6-yl)methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 7-bromo-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (40.8 mg, 179 μmol), bis(dibenzylideneacetone)palladium (6.86 mg, 11.9 μmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 mL), the reaction was stirred at 100°C for 12 h, and the reaction solution was concentrated to obtain the crude product. The crude product was then separated and purified by silica gel column (petroleum ether: ethyl acetate (V / V) = 5:1-1:1) to obtain the target compound 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridine-3(2H)-one (Compound I-3) (20.0 mg, yield 38.1%).

[0334] The products were separated by SFC (chromatographic column: Chiralpak AD-3 50×4.6 mm ID, 3 μm, mobile phase: mobile phase A: CO2, mobile phase B: IPA+ACN (0.05 vol% DEA);

[0335] Isocratic elution: 50 vol% IPA + ACN (0.05 vol% DEA) in CO2, flow rate: 3 mL / min; detector: PDA, column temperature: 35°C; column pressure: 100 bar. The isomer (Compound I-3A (i.e., the compound represented by Formula I-3A of the present application)) (RT = 0.743 min) and the isomer (Compound I-3B (i.e., the compound represented by Formula I-3B of the present application, which has been confirmed to have the following structure)) (RT = 1.670 min) were obtained.

[0336] 1 H NMR(400MHz,DMSO)δ8.04(d,1H),7.81(d,1H),7.61(d,1H),6.68(d,1H),6.58(dd,2.0Hz,1H),3.90(d,1H),3.70 -3.52(m,5H),3.48(s,3H),2.18(dt,1H),2.13-1.93(m,5H),1.06(dd,2H).

[0337] LC-MS, M / Z(ESI):441.1[M+H]+ .

[0338] Example 1-1 Preparation of the compound represented by formula I-3B

[0339] The synthetic route of the target compound is as follows:

[0340] Step 1: Synthesis of methyl (1aS, 7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylate (3).

[0341] To a reaction flask were added methyl (1aS,7bR)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylate (R1) (159.6 mg, 0.7 mmol), 7-bromo-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (2) (130 mg, 0.6 mmol), Pd2(dba)3 (91.6 mg, 0.1 mmol), ligand L (ligand L is Xantphos) (57.9 mg, 0.1 mmol), and cesium carbonate (488.7 mg, 1.5 mmol). After nitrogen purging three times, anhydrous 1,4-dioxane (4 mL) was added and the reaction was continued at 85°C for 12 hours. After cooling to room temperature, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was concentrated to dryness and then mixed. The mixture was separated and purified on a silica gel column (dichloromethane:methanol, V / V=20:1) to obtain methyl (1aS,7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylate (3) (200 mg, yield: 85.7%).

[0342] LC-MS, M / Z(ESI):352.1[M+H] + .

[0343] Ligand L:

[0344] Step 2: Synthesis of (1aS,7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid (4).

[0345] Methyl (1aS,7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylate (3) (200 mg, 0.6 mmol) was dissolved in a mixed solution of tetrahydrofuran (4 mL), methanol (0.8 mL) and water (0.8 mL), and then lithium hydroxide monohydrate (100 mg, 2.4 mmol) was added. The mixture was reacted at room temperature for 12 hours. After the reaction was complete, water was added to quench the reaction. 1 M hydrochloric acid was added to adjust the pH to 1. The mixture was extracted with ethyl acetate. The organic phase was concentrated to dryness to obtain (1aS,7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid (4), which was used directly in the next reaction.

[0346] LC-MS, M / Z(ESI):338.1[M+H] + .

[0347] Step 3: Synthesis of 7-((1aS,7bR)-6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropyl[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (5).

[0348] Under nitrogen protection, to a solution of (1aS,7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid (4) (120 mg, 0.4 mmol) in ethyl acetate (2 mL) were added 4,4-difluoropiperidine hydrochloride (72.7 mg, 0.6 mmol) and pyridine (0.2 mL), and then a DMF solution of T3P (0.68 mL, 0.5 mmol) was added, and the reaction was carried out at room temperature for 3 hours. The reaction was quenched by adding water, and the mixture was extracted with ethyl acetate. The organic phase was concentrated to dryness and then mixed. The mixture was separated and purified by silica gel column chromatography (dichloromethane:methanol, V / V=20:1) to obtain 7-((1aS,7bR)-6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropyl[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (5) (132 mg, yield: 75%).

[0349] LC-MS, M / Z(ESI):441.1[M+H]+

[0350] 1 H NMR (400MHz, DMSO-d6): δ8.09(d,1H),7.71(d,1H),7.59(d,1H),6.55–6.52(m,2H),3 .95(d,1H),3.75–3.69(m,5H),3.63(s,3H),2.10–2.03(m,6H),1,22–1.12(m,2H)ppm.

[0351] The product was subjected to SFC (chromatographic column: Chiralpak AD-3 50×4.6 mm ID, 3 μm, mobile phase: mobile phase A: CO2, mobile phase B: IPA+ACN (0.05 vol% DEA);

[0352] Isocratic elution: 50 vol% IPA + ACN (0.05 vol% DEA) in CO2, flow rate: 3 mL / min; detector: PDA, column temperature: 35°C; column pressure: 100 Bar. The retention reagent RT of compound I-3B (i.e., the compound represented by formula I-3B of the present application) was 1.674 min.

[0353] Single crystal preparation method: Weigh 5 mg of (1aS,7bR)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid methyl ester (R1) into a 2 mL liquid chromatography flask. Add 0.4 mL of ethyl acetate to dissolve the mixture. Then, add 0.6 mL of petroleum ether and mix thoroughly. The liquid chromatography flask is allowed to stand at room temperature. After the solvent evaporates naturally (approximately 2 days), colorless, transparent crystals are obtained. Single crystal structure analysis is performed. The single crystal structure of compound R1 is shown in Figure 31. Its main crystal parameters are as follows:

[0354] Recrystallization of the free base is difficult and prone to gel precipitation. The free base of the compound represented by Formula I-3B obtained in Example 1 dissolved clearly in a toluene / dimethyl ether solvent system without solid precipitation. Prolonged stirring in a THF / MTBE system can precipitate solids, but the time required is long and not conducive to factory scale-up production. Large solids are easily produced during the gel solidification process, and the sample is severely agglomerated, easily blocking the stirring paddle and making it difficult to stir.

[0355] Example 2 Crystalline Form A of the Compound of Formula I-3B

[0356] The compound of formula I-3B obtained in Example 1 (RT=1.670 min) was slowly cooled in IPAc and then evaporated to room temperature to obtain Form A of the compound of formula I-3B. Characterization data are as follows:

[0357] The XRPD diffraction peak data of the crystalline form A of the compound represented by formula I-3B are shown in the following table:

[0358] The characterization data of Form A of the compound represented by Formula I-3B are shown in the following table:

[0359] The NMR data of Form A of the compound represented by Formula I-3B are as follows:

[0360] According to NMR, the molar ratio of the residual solvent IPAc to the compound of Formula I-3B is approximately 0.04:1 (0.9 wt%). It is speculated that the crystalline form A of the compound of Formula I-3B is an anhydrous crystalline form.

[0361] Variable temperature XRPD heating experiment:

[0362] To investigate the crystalline properties of Form A of the compound represented by Formula I-3B, Form A of the compound represented by Formula I-3B was heated to 100°C to 180°C in a nitrogen flow, and a variable temperature XRPD (VT-XRPD) experiment was performed on the sample. The results are shown in Figure 3. Comparing the sample at 30°C without nitrogen (30°C, No N2) and the sample with nitrogen (30°C, N2), the sample was heated to 100°C and 150°C under N2 protection (100°C, N2 and 150°C, N2). The crystalline form did not change. After heating to 180°C (180°C, N2) and cooling to room temperature (cooling to 30°C, N2), the crystalline form transformed into an amorphous form. It is speculated that Form A of the compound represented by Formula I-3B is an anhydrous crystalline form.

[0363] Example 3: Preparation of Form B of the Compound of Formula I-3B

[0364] The compound of formula I-3B obtained in Example 1 (RT = 1.670 min) was suspended and stirred in MeOH / H2O (1:5, v:v) at 50°C for 3 days to obtain Form B of the compound of formula I-3B. The crystalline form B was dried at room temperature overnight and then characterized.

[0365] The XRPD diffraction peak data of the crystalline form B of the compound represented by formula I-3B are shown in the following table:

[0366] The characterization data of Form B of the compound represented by Formula I-3B are as follows:

[0367] The NMR data of Form B of the compound represented by Formula I-3B are as follows:

[0368] No residual solvent was observed in the NMR data, and Form B was an anhydrous crystalline form.

[0369] Variable temperature XRPD experiment:

[0370] To investigate the crystalline properties of Form B of the compound represented by Formula I-3B, variable temperature XRPD (VT-XRPD) experiments were performed on the samples heated to 100°C to 180°C in a nitrogen flow. The results are shown in Figure 6. Comparing the samples heated at 30°C without nitrogen (30°C, No N2) and in the presence of nitrogen (30°C, N2), the crystal form remained unchanged after heating to 100°C and 150°C under N2 protection (100°C, N2 and 150°C, N2). However, after heating to 180°C (180°C, N2) and cooling to room temperature (cooling to 30°C, N2), the crystal form transformed into an amorphous form. It is speculated that Form B of the compound represented by Formula I-3B is an anhydrous crystalline form.

[0371] Example 4 Preparation of a salt of the compound represented by formula I-3B or a solvate thereof

[0372] 4.1 Crystalline Form of the Hydrochloride Salt of the Compound Represented by Formula I-3B

[0373] The crystalline form A of the compound represented by Formula I-3B and an equimolar ratio of equimolar amounts of hydrochloric acid (37% hydrochloric acid aqueous solution) were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature overnight to form a jelly. The jelly was subjected to a temperature cycle (50°C to 5°C, a heating rate of 4.5°C / min, a constant temperature of 50°C for 2 hours, a cooling rate of 0.1°C / min, a constant temperature of 5°C for 2 hours, a total of 6 cycles) for about 5 days to obtain a crystalline form of the hydrochloride salt of the compound represented by Formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0374] The XRPD diffraction peak data of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B are shown in the following table:

[0375] The crystal characterization data of the hydrochloride salt of the compound represented by formula I-3B are as follows:

[0376] The NMR data of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B are as follows:

[0377] According to NMR data, the molar ratio of the residual solvent acetone to the compound of formula I-3B was 0.9 (10.3 wt%). HPLC / IC results showed that the molar ratio of hydrochloric acid to the compound of formula I-3B was 0.9.

[0378] 4.2 Crystalline Form of Phosphate Salt of the Compound Represented by Formula I-3B

[0379] Form A of the compound represented by Formula I-3B and an equimolar amount of phosphoric acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain a crystalline form of the phosphate salt of the compound represented by Formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0380] The XRPD diffraction peak data of the crystalline form of the phosphate salt of the compound represented by Formula I-3B are shown in the following table:

[0381] The crystal characterization data of the phosphate salt of the compound represented by formula I-3B are shown in the following table:

[0382] The NMR data of the crystalline form of the phosphate salt of the compound represented by formula I-3B:

[0383] According to NMR data, the molar ratio of the residual solvent acetone to the compound of Formula I-3B was 0.05 (0.5 wt%). HPLC / IC results showed that the molar ratio of phosphoric acid to the compound of Formula I-3B was 1.0.

[0384] 4.3 Crystalline Form of Fumaric Acid Complex of the Compound Represented by Formula I-3B

[0385] Method 1: 300.6 mg of Form A of the compound represented by Formula I-3B and 80.0 mg of an equimolar amount of fumaric acid were weighed into a 5-mL vial, 3 mL of acetone / n-heptane (1:1, v:v) was added, and the mixture was suspended and stirred at room temperature for 3 days. The mixture was centrifuged at room temperature to obtain a fumaric acid complex of the compound represented by Formula I-3B.

[0386] The XRPD diffraction peak data of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B are shown in the following table:

[0387] The crystal characterization data of the fumaric acid complex of the compound represented by formula I-3B are as follows:

[0388] The NMR data of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B are as follows:

[0389] To further investigate the molecular structure of the crystals, single crystals of a fumaric acid complex of the compound represented by Formula I-3B were obtained by Method 2. Method 2: The compound represented by Formula I-3B (~15 mg) was weighed and added to an EP tube. Acetone (0.75 mL) was added and shaken until the sample dissolved. The solution was filtered through a microporous filter membrane into a 2 mL transparent glass bottle. N-heptane (0.75 mL) was added. The solution was separated into layers and sealed with a sealing film. Two small holes were pierced and the solution was allowed to evaporate at room temperature for about 2 days to obtain transparent crystals precipitated to obtain a fumaric acid complex of the compound represented by Formula I-3B (single crystal).

[0390] The single crystal of the fumaric acid complex of the compound represented by formula I-3B obtained in method 2 was subjected to X-ray single crystal diffraction, and the crystallographic parameters were measured as follows:

[0391] X-ray single crystal diffraction results indicate that fumaric acid and the compound represented by Formula I-3B are connected by hydrogen bonds. The distance between the hydrogen atom and the oxygen atom is 0.84 Å, and the distance between the hydrogen atom and the nitrogen atom is 1.89 Å. The hydrogen atom is closer to the oxygen atom, indicating that the single crystal sample forms a cocrystal (i.e., (1aS,7bR)-7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-onefumaric acid cocrystal). The molar ratio of fumaric acid to the compound represented by Formula I-3B is 1.0, and no residual solvent signal was observed by NMR.

[0392] The crystal hydrogen bonding of the fumaric acid complex of the compound represented by formula I-3B ( and °) are shown in the following table:

[0393] The molecular structure ellipsoid model of a single crystal of the fumaric acid complex of the compound represented by Formula I-3B is shown in FIG49 , and a comparison of its fitted XRPD diffraction pattern with the measured XRPD diffraction pattern of the crystal obtained by Method 1 is shown in FIG48 . The results indicate that the complex crystals obtained by Method 1 and Method 2 are of the same crystalline form.

[0394] 4.4 Crystalline Form of L-Tartrate Salt of the Compound Represented by Formula I-3B

[0395] Method 1: Form A of the compound represented by Formula I-3B and an equimolar amount of tartaric acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B, which was then vacuum-dried at room temperature overnight and characterized.

[0396] Method 2: 299.7 mg of Form A of the compound represented by Formula I-3B and 102.5 mg of an equimolar amount of L-tartaric acid were weighed into a 5-mL vial, 3 mL of acetone / n-heptane (1:1, v:v) was added, and the mixture was suspended and stirred at room temperature for 3 days. The mixture was centrifuged at room temperature to obtain the crystalline form of L-tartrate of the compound represented by Formula I-3B.

[0397] The XRPD diffraction peak data of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B are shown in the following table:

[0398] The crystal characterization data of the L-tartrate salt of the compound represented by formula I-3B are as follows:

[0399] The NMR data of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B are as follows:

[0400] The molar ratio of tartaric acid to the compound represented by Formula I-3B is 1.0, and no residual solvent signal is observed in the NMR data.

[0401] 4.5 Crystalline Form of the p-Toluenesulfonate Salt of the Compound Represented by Formula I-3B

[0402] Method 1: Form A of the compound represented by Formula I-3B and an equimolar amount of p-toluenesulfonic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain a crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B, which was then vacuum-dried at room temperature overnight and characterized.

[0403] Method 2: 300.9 mg of Form A of the compound represented by Formula I-3B and 130.8 mg of an equimolar amount of p-toluenesulfonic acid monohydrate were weighed into a 5-mL vial, 3 mL of acetone / n-heptane (1:1, v:v) was added, and the mixture was suspended and stirred at room temperature for 3 days. The mixture was centrifuged at room temperature to obtain a crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B.

[0404] The XRPD diffraction peak data of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B are shown in the following table:

[0405] The crystal characterization data of the p-toluenesulfonate salt of the compound represented by Formula I-3B are shown in the following table:

[0406] The crystalline NMR of the p-toluenesulfonate salt of the compound represented by formula I-3B is as follows:

[0407] The molar ratio of p-toluenesulfonic acid to the compound represented by Formula I-3B is 1.0, and no residual solvent signal is observed in the NMR data.

[0408] 4.6 Crystalline Form of L-Malate Salt of the Compound Represented by Formula I-3B

[0409] The crystalline form A of the compound represented by Formula I-3B and an equimolar amount of malic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature overnight to form a jelly, which was then subjected to a temperature cycle (50°C to 5°C, a heating rate of 4.5°C / min, constant temperature at 50°C for 2 hours, a cooling rate of 0.1°C / min, constant temperature at 5°C for 2 hours, for a total of 6 cycles) for about 5 days to obtain the crystalline form of the L-malate salt of the compound represented by Formula I-3B, which was then dried in vacuo at room temperature overnight and characterized.

[0410] The XRPD diffraction peak data of the crystalline form of the L-malate salt of the compound represented by Formula I-3B are shown in the following table:

[0411] The crystal characterization data of the L-malate salt of the compound represented by formula I-3B are as follows:

[0412] The NMR of the crystal form of the L-malate salt of the compound represented by formula I-3B:

[0413] The signal of malic acid was observed in the NMR data, with a molar ratio of malic acid to the compound represented by Formula I-3B of 1.0, and no residual solvent signal was observed.

[0414] 4.7 Form A of the edisylate salt of the compound represented by Formula I-3B

[0415] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of ethanedisulfonic acid were suspended and stirred in IPA at room temperature for 8 days to obtain the crystalline form of L-malate of the compound represented by formula I-3B, which was then vacuum dried at room temperature overnight and characterized.

[0416] The XRPD data of Form A of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0417] The characterization data of Form A of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0418] The NMR data of Form A of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0419] According to NMR data, the molar ratio of ethanedisulfonic acid to the compound represented by Formula I-3B is 0.5, and the molar ratio of solvent IPA to the compound represented by Formula I-3B is 0.5 (5.5 wt %).

[0420] 4.8 Form B of the edisylate salt of the compound represented by Formula I-3B

[0421] The crystalline form A of the compound represented by Formula I-3B and an equimolar amount of ethanedisulfonic acid were suspended and stirred in IPAc at room temperature overnight to form a colloid. The colloid was subjected to a temperature cycle (50°C to 5°C, a heating rate of 4.5°C / min, a constant temperature of 50°C for 2 hours, a cooling rate of 0.1°C / min, a constant temperature of 5°C for 2 hours, a total of 6 cycles) for about 5 days to obtain the crystalline form B of the ethanedisulfonate salt of the compound represented by Formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0422] The XRPD diffraction peak data of Form B of the edisylate salt of the compound represented by Formula I-3B are shown in the following table:

[0423] The characterization data of Form B of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0424] The NMR data of Form B of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0425] The molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B was 0.5, and no residual solvent was observed by NMR data.

[0426] 4.9 Form C of the edisylate salt of the compound represented by Formula I-3B

[0427] The crystalline form A of the compound represented by Formula I-3B and an equimolar amount of ethanedisulfonic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature overnight to form a jelly. The jelly was subjected to a temperature cycle (50°C to 5°C, a heating rate of 4.5°C / min, a constant temperature of 50°C for 2 hours, a cooling rate of 0.1°C / min, a constant temperature of 5°C for 2 hours, a total of 6 cycles). After about 5 days, it remained a jelly. After volatilization at room temperature, it was vacuum dried to obtain the crystalline form C of the ethanedisulfonic acid salt of the compound represented by Formula I-3B, which was characterized at room temperature.

[0428] The XRPD diffraction peak data of Form C of the edisylate salt of the compound represented by Formula I-3B are shown in the following table:

[0429] The characterization data of Form C of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0430] The NMR data of Form C of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0431] The molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B is 1.0, the molar ratio of solvent acetone to the compound represented by formula I-3B is 0.3 (2.3 wt%), and the molar ratio of solvent n-heptane to the compound represented by formula I-3B is 0.03 (0.5 wt%).

[0432] 4.10 Crystalline Form of Methanesulfonate of the Compound Represented by Formula I-3B

[0433] Form A of the compound represented by Formula I-3B and an equimolar amount of methanesulfonic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature overnight to form a jelly. The jelly was then subjected to a temperature cycle (50°C to 5°C, heating rate 4.5°C / min, constant temperature at 50°C for 2 hours, cooling rate 0.1°C / min, constant temperature at 5°C for 2 hours, for a total of 6 cycles) for approximately 5 days to obtain a crystalline form of the mesylate salt of the compound represented by Formula I-3B. The crystalline form was then dried in vacuo at room temperature overnight and characterized. The XRPD diffraction peak data for the crystalline form of the mesylate salt of the compound represented by Formula I-3B are shown in the following table:

[0434] The crystal characterization data of the mesylate salt of the compound represented by formula I-3B are as follows:

[0435] The crystal NMR data of the mesylate salt of the compound represented by formula I-3B are as follows:

[0436] The molar ratio of methanesulfonic acid to the compound represented by formula I-3B is 1.0, and the molar ratio of the residual solvent n-heptane to the compound represented by formula I-3B is 0.008 (0.2 wt %).

[0437] 4.11 Crystalline Form of Benzenesulfonate Salt of the Compound Represented by Formula I-3B

[0438] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of benzenesulfonic acid were suspended and stirred in IPA at room temperature for 8 days to obtain the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B, which was then vacuum dried at room temperature overnight and characterized.

[0439] The XRPD diffraction peak data of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B are shown in the following table:

[0440] The crystal characterization data of the benzenesulfonate salt of the compound represented by formula I-3B are shown in the following table:

[0441] The NMR data of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B:

[0442] The molar ratio of benzenesulfonic acid to the compound represented by formula I-3B is 1.0, and the molar ratio of the residual solvent IPA to the compound represented by formula I-3B is 0.01 (0.1 wt %).

[0443] 4.12 Crystalline Form of Oxalate Salt of the Compound Represented by Formula I-3B

[0444] The crystalline form A of the compound represented by Formula I-3B and an equimolar amount of oxalic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain the crystalline form of the oxalate salt of the compound represented by Formula I-3B, which was then vacuum dried at room temperature overnight and characterized.

[0445] The XRPD diffraction peak data of the crystalline form of the oxalate salt of the compound represented by Formula I-3B are shown in the following table:

[0446] The crystal characterization data of the oxalate salt of the compound represented by formula I-3B are shown in the following table:

[0447] The NMR data of the crystalline form of the oxalate salt of the compound represented by Formula I-3B are as follows:

[0448] No residual solvent signal was observed in the NMR data. HPLC / IC results showed that the molar ratio of oxalic acid to the compound represented by Formula I-3B was 1.4.

[0449] Effect Example 1 Effect Test of the Compound Represented by Formula I-3B

[0450] Use Assay Buffer (50mM Tris-HCl, pH 7.5, 0.01% Tween 20 by volume) to prepare 15-PGDH (R&D Systems, catalog number 5660-DH-010) to twice the final concentration, i.e. 30nM. Then add it to a 384 white plate (Cisbio Bioassays, catalog number 66PL384025) at 8μl / well. Set up a negative control well, add only Assay Buffer without enzyme. Then use Assay Buffer to prepare the compound to 4 times the final concentration, i.e. starting at 4000nM, 3-fold dilution, 10 concentrations. Add it to the above white plate at 4μl / well, mix well, centrifuge at 1000rpm for 1min, and incubate at 25°C for 10min. At the same time, set up positive control wells (only 15-PGDH) and negative control wells (no 15-PGDH). Then use Assay Buffer to prepare NAD +(Sellect. Product No. S2518) and PGE2 (R&D Systems, Product No. 2296 / 10) were mixed. + and PGE2 were prepared to 4 times the final concentration, i.e., 2 mM and 0.12 mM. Then, 4 μl / well was added to the above white plate, mixed, centrifuged at 1000 rpm for 1 minute, and incubated at 25°C for 30 minutes to allow the reaction to proceed. Detection was performed using a TECAN SPARK 20M instrument at an excitation wavelength of 340 nm and an emission wavelength of 485 nm. Four-parameter fitting was performed using GraphPad Prism 8.0 to calculate IC values. 50 value.

[0451] Results of the 15-PGDH inhibition test of the compound obtained in Example 1

[0452] The experimental results show that the compound of the present invention has a significant inhibitory effect on 15-PGDH.

[0453] Effect Example 2: Effect of Compounds on PGE2 Levels in A549 Cell Supernatant

[0454] A549 cells (Wuhan Punosai) were cultured in F12K+10% FBS. Cells in good logarithmic phase were used for the experiment. The cells were digested and counted, and the cells were seeded into 24-well plates at 8,000 cells / well. The cells were placed in a 37°C, 5% CO2 incubator for overnight culture. After the cells adhered, the culture medium containing 0.5% FBS was changed to treat for about 10 hours, and IL-1β (final concentration 20 ng / mL, 1 mL / well) was added to each well. At the same time, a control group was set up (IL-1β was not added to the control group). After IL-1β stimulated for about 24 hours, the cell culture fluid in each well was discarded, and each well was gently washed with fresh culture medium containing 0.5% FBS, and then 400 μL of culture medium containing the compound obtained in Example 1 (20 nM and 2500 nM) at each concentration was added to each well for about 12 hours. The supernatant was collected and PGE2 was detected using an ELISA kit (R&D Systems, Cat. No. KGE004B).

[0455] The compound obtained in Example 1 increases PGE2 in the supernatant of A549 cells by multiple times as shown in the following table:

[0456] The experimental results show that the compound of the present invention can significantly increase the production of PGE2.

[0457] Effect Example 3: Pharmacological Efficacy Experiment in IPF Prevention Model of Mice

[0458] Male mice were acclimated for 1-2 weeks and after reaching the target weight (25 g), an IPF model (idiopathic pulmonary fibrosis model) was induced with a certain dose of bleomycin. On the day of modeling, the mice were randomly divided into a model group and a treatment group based on their weight. The treatment group was administered nintedanib (60 mg / kg, once daily (qd)) and compound I-3B obtained in Example 1 (2.5 mg / kg, twice daily (bid)). Oral gavage was initiated daily. The vehicle control group was given a blank solvent for 21 consecutive days. Body weight was measured every 3 days during the treatment period. On the last day of dosing, the animals were euthanized, and the lungs were removed starting from the thyroid cartilage (no perfusion was required). 10% formalin was slowly perfused into the lungs until both lungs were filled. After ligation of the aorta, the animals were fixed in 5-10 times the tissue volume of 10% formalin. Paraffin tissue sections were prepared for the left lung, stained with HE and Masson Trichrome, and panoramic scanning of the sections was performed using a Hamamatsu NanoZoomer Digital Pathology (S210) slice scanner for pathological analysis.

[0459] The pathological evaluation indicators of pulmonary fibrosis are shown in the table below

[0460] The summary table of pulmonary fibrosis scores (mean values) is shown in the following table:

[0461] The experimental results show that the compound of the present invention can significantly reduce the degree of fibrosis in the IPF prevention model of mice.

[0462] Effect Example 4: Pharmacological Efficacy Experiment in Mouse IPF Treatment Model

[0463] Male mice were acclimated for 1-2 weeks and, after reaching the target body weight (25 g), an IPF model (idiopathic pulmonary fibrosis model) was induced with a dose of bleomycin. On the day of modeling, the mice were randomly divided into a model group and a treatment group based on body weight. The treatment groups received nintedanib (60 mg / kg, daily), a low dose of compound I-3B obtained in Example 1 (1 mg / kg, bid), and a high dose of compound I-3B obtained in Example 1 (2.5 mg / kg, bid). The treatment groups were administered oral gavage daily starting on Day 7. The vehicle control group received blank vehicle for 14 consecutive days. Body weights were measured twice weekly during the treatment period. On the last day of dosing, the animals were euthanized, and the lungs were removed starting from the thyroid cartilage (no perfusion was required). 10% formalin was slowly perfused into the lungs until both lungs were filled. After ligation of the aorta, the animals were fixed in 5-10 times the tissue volume of 10% formalin. Paraffin tissue sections were prepared for the left lung, stained with HE and Masson Trichrome, and panoramic scanning of the sections was performed using a Hamamatsu NanoZoomer Digital Pathology (S210) slice scanner for pathological analysis.

[0464] The pathological evaluation indicators of pulmonary fibrosis are shown in the table below:

[0465] The summary table of pulmonary fibrosis scores (mean values) is shown in the table below.

[0466] The experimental results show that the compound of the present invention can significantly reduce the degree of fibrosis in the IPF treatment model of mice.

[0467] Effect Example 5: Experimental study on the efficacy of liver resection and regeneration in mice

[0468] Eight-week-old male C57BL / 6J mice (20-24g) were anesthetized and fixed with the abdomen facing upward. The surgical site was shaved and disinfected with iodine. A transverse incision of approximately 1.5-2 cm was made in the abdomen, and the bilateral epigastric arteries were clamped with hemostatic clips. After opening the abdominal cavity, each liver lobe was freed and the hilum of the lobe to be resected was ligated with surgical suture. After the sutures darkened, the left lateral and middle lobes of the liver were resected. After the residual blood in the abdominal cavity was cleaned, the muscle layer and fur layer were sutured layer by layer. Postoperative care was taken. Drug administration began on the day of model establishment. Eight animals were sacrificed on day 1 and day 3 of drug administration. The intact liver tissue was weighed and compared with the model group to evaluate the drug's effect on promoting liver regeneration.

[0469] The experimental results show that the compound of the present invention can significantly promote liver regeneration.

[0470] Effect Example 6: Pharmacokinetics in mice

[0471] The pharmacokinetic properties of the compound obtained in Example 1 in mice were determined according to the following experimental methods.

[0472] Three male CD-1 mice were administered a 10 mg / kg dose via oral gavage in a vehicle of 5% DMSO + 10% Solutol + 85% Saline. The mice were fasted overnight, and blood was collected before dosing and at 15, 30 minutes, and 1, 2, 4, 6, 8, and 24 hours after dosing. Blood samples were centrifuged at 6800g for 6 minutes at 2-8°C, and plasma was collected and stored at -80°C. At each time point, 10 μL of plasma was added to 200 μL of methanol containing 100 ng / mL internal standard, vortexed, and centrifuged at 18,000g for 7 minutes at 2-8°C. 200 μL of the sample was transferred to a 96-well plate for LC-MS / MS analysis. Key pharmacokinetic parameters were analyzed using a non-compartmental model using WinNonlin 7.0 software.

[0473] The pharmacokinetic data of mice are shown in the table below:

[0474] The experimental results show that the compound of the present invention exhibits excellent pharmacokinetic properties in mice.

[0475] Effect Example 7: IBD efficacy in mice

[0476] Female C57BL / 6 mice aged 6-8 weeks were divided into five groups: G1-G5, which were a normal control group, a model control group, a positive control group, a low-dose group of compound I-3B obtained in Example 1, and a high-dose group of compound I-3B obtained in Example 1. Groups G2-G6 were given a 2% DSS aqueous solution on days 0-6, normal water on days 0-10, and vehicle / positive / test substances on days 0-9. After euthanasia on day 10, the mice were autopsied and their intestinal weight (CW) and intestinal length (CL) were measured, and intestinal tissue (BW) was histopathologically examined. The results showed that compared with the G2 model group, the G3-positive control group (cyclosporine CsA 25 mg / kg-qd) had significantly increased body weight, a significantly decreased DAI, a significantly increased CL, and significantly decreased CW, CL / CW / BW, and CL / CW. Pathological examination of the colonic tissue of the model animals showed decreased inflammatory cell infiltration and tissue damage scores, but no significant differences were found. The body weight of animals in the G4-Compound I-3B (2.5 mg / kg-bid) and G5-Compound I-3B (5 mg / kg-bid) groups increased, with the body weight of G5 animals increasing significantly; the DAI of the animals decreased significantly, the CL increased significantly, and the CW, CL / CW / BW, and CL / CW decreased significantly; the results of colon tissue pathology examination showed that the inflammatory cell infiltration and tissue damage scores decreased significantly.

[0477] The colon length (CL), colon weight (CW), CL / CW / BW, and CW / CL of each group of animals are summarized in the table below:

[0478] The experimental results showed that compound I-3B (2.5 mg / kg and 5 mg / kg) can significantly improve IBD symptoms and tissue damage in mice, and its therapeutic effect is better than that of positive control.

[0479] Effect Example 8: Crystalline Dynamic Solubility Stability Test

[0480] The dynamic solubility of the crystal form A of the compound represented by Formula I-3B and the crystal form of the fumaric acid complex of the compound represented by Formula I-3B in H2O, SGF, FaSSIF and FeSSIF was tested at 37°C.

[0481] The above samples were mixed with rotation at 37°C at a concentration of 10 mg / mL (based on the compound of Formula I-3B), and the solubility of each sample was measured at different time points (1, 4, and 24 hours). Samples were collected at each time point, centrifuged (12,000 rpm, 2 minutes), and filtered (0.45 μm PTFE membrane). The filtrate concentration and pH were determined by HPLC, and the solid sample after centrifugation was analyzed by XRPD.

[0482] The results of the dynamic solubility test are shown in the following table:

[0483] S: concentration of the compound represented by Formula I-3B (mg / mL); FC: crystal transformation, --: not tested.

[0484] The results show that Form A of the compound represented by Formula I-3B and the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B have good solubility in various solvents. The XRPD results are shown in Figures 32, 33, 34, 35, 36, 37, 38, and 39. Comparison of the data at the start, 1 hour, 4 hours, and 24 hours of the test for each sample shows that Form A of the compound represented by Formula I-3B and the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B did not undergo any change in crystalline form in the various systems tested, indicating good stability.

[0485] Effect Example 9: Solid-state stability evaluation experiment

[0486] Samples of crystalline form A of the compound represented by formula I-3B, crystalline form B of the compound represented by formula I-3B, crystalline form of the fumaric acid complex of the compound represented by formula I-3B, and crystalline form of the tartrate salt of the compound represented by formula I-3B were placed under the conditions of 60°C / closed / 1 day, 25°C / 60% RH / open / 1 week, and 40°C / 75% RH / open / 1 week, respectively, and their physical and chemical stabilities were evaluated by XRPD and HPLC.

[0487] The purity and stability test data of the samples are as follows:

[0488] The HPLC test data of Form A of the compound represented by Formula I-3B are as follows:

[0489] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0490] The HPLC test data of Form B of the compound represented by Formula I-3B are as follows:

[0491] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0492] The HPLC test data of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B are as follows:

[0493] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0494] The HPLC test data of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B are as follows:

[0495] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0496] The XRPD results are shown in Figures 40, 41, 42, and 43. The results show that each tested crystalline form maintained good purity after a period of storage, with essentially no significant change in HPLC purity. No changes in crystalline form were observed for each tested crystalline form, indicating high stability.

[0497] Effect Example 10: Moisture-attracting Test

[0498] DVS was used to evaluate the hygroscopicity of the crystalline form A of the compound shown in Formula I-3B, the crystalline form B of the compound shown in Formula I-3B, the crystalline form of the fumaric acid complex of the compound shown in Formula I-3B, and the crystalline form of the tartrate salt of the compound shown in Formula I-3B.

[0499] The results showed that the test samples had good hygroscopicity. The XRPD results of the samples after DVS test are listed in Figures 44, 45, 46 and 47. Comparing the data before and after the DVS test, the hygroscopicity evaluation results showed that the crystalline form A of the compound represented by Formula I-3B had a moisture absorption weight gain of 1.112% at 25°C / 80% RH, and there was no change in the crystal form after the test; the crystalline form B of the compound represented by Formula I-3B had a moisture absorption weight gain of 0.1309% at 25°C / 80% RH, the sample had no hygroscopicity, and there was no change in the crystal form after the test; the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B had a moisture absorption weight gain of 0.0880% at 25°C / 80% RH, the sample had no hygroscopicity, and there was no change in the crystal form after the test; the crystalline form of the tartrate salt of the compound represented by Formula I-3B had a moisture absorption weight gain of 0.2291% at 25°C / 80% RH, the sample had slight hygroscopicity, and there was no change in the crystal form after the test.

[0500] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.

Claims

1. A pharmaceutically acceptable salt of a heterocyclic compound or a solvate thereof, characterized in that: The heterocyclic compound is a compound represented by formula I-3A and / or a compound represented by formula I-3B; Wherein, the pharmaceutically acceptable salt is a salt formed by a heterocyclic compound and an acid; the acid is selected from hydrochloric acid, phosphoric acid, fumaric acid, tartaric acid, malic acid, ethanedisulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or oxalic acid.

2. The pharmaceutically acceptable salt or solvate of the heterocyclic compound according to claim 1, characterized in that: The pharmaceutically acceptable salt of the heterocyclic compound or its solvate satisfies one or more of the following conditions: (1) In the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the solvent is selected from one or two of isopropyl acetate, acetone, isopropanol and n-heptane; (2) When the heterocyclic compound is a compound represented by formula I-3A or a compound represented by formula I-3B, it is a compound represented by formula I-3: (3) In the pharmaceutically acceptable salt of the heterocyclic compound or a solvate thereof, the molar ratio of the heterocyclic compound to the acid is 1:(0.5-2), such as 1:(0.5-1), and further such as 1:1, 1:0.9 or 1:0.5; (4) The heterocyclic compound is a compound represented by formula I-3B (5) the solvate of the pharmaceutically acceptable salt of the heterocyclic compound is not the monohydrochloride monohydrate of the heterocyclic compound; and (6) In the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the molar ratio of the heterocyclic compound to the solvent is 1:(0.001-2), for example 1:(0.001-1), for example 1:0.05, 1:0.9, 1:0.01, 1:0.04, 1:0.008, 1:0.03, 1:0.3 or 1:0.

5.

3. The pharmaceutically acceptable salt or solvate of the heterocyclic compound according to claim 1, characterized in that: The pharmaceutically acceptable salt or solvate of the heterocyclic compound is: The compound of formula I-3B: the hydrochloride acetone solvate of the compound of formula I-3B, wherein the molar ratio of hydrochloric acid, the compound of formula I-3B and acetone is 0.9:1:0.9; Or, a phosphate of the compound of formula I-3B, wherein the molar ratio of phosphoric acid to the compound of formula I-3B is 1:1; Or, a phosphate acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of phosphoric acid, the compound represented by formula I-3B and acetone is 1:1:0.05; Or, a fumarate salt of the compound of formula I-3B, wherein the molar ratio of fumaric acid to the compound of formula I-3B is 1:1; Or, L-tartrate of the compound of formula I-3B, wherein the molar ratio of tartaric acid to the compound of formula I-3B is 1:1; Or, L-malate of the compound of formula I-3B, wherein the molar ratio of malic acid to the compound of formula I-3B is 1:1; Or, an isopropanol solvate of an edisulphonate of the compound of formula I-3B, wherein the molar ratio of edisulphonic acid, the compound of formula I-3B and isopropanol is 0.5:1:0.5; Or, ethanedisulfonate of the compound represented by formula I-3B, wherein the molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B is 0.5:1; Or, an edisulphonate of the compound represented by formula I-3B, wherein the molar ratio of edisulphonic acid to the compound represented by formula I-3B is 1:1; Or, ethanedisulfonic acid salt of the compound represented by formula I-3B and acetone n-heptane solvate, wherein the molar ratio of ethanedisulfonic acid, the compound represented by formula I-3B, acetone and n-heptane is 1:1:0.3:0.03; Or, p-toluenesulfonate of the compound represented by formula I-3B, wherein the molar ratio of p-toluenesulfonate to the compound represented by formula I-3B is 1:1; Or, a methanesulfonate salt of the compound of formula I-3B, wherein the molar ratio of methanesulfonic acid to the compound of formula I-3B is 1:1; Or, a methanesulfonate n-heptane solvate of the compound represented by formula I-3B, wherein the molar ratio of methanesulfonic acid, the compound represented by formula I-3B and n-heptane is 1:1:0.008; Or, a benzenesulfonate salt of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid to the compound represented by formula I-3B is 1:1; Or, a benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid, the compound represented by formula I-3B and isopropanol is 1:1:0.01; Or, an oxalate of the compound represented by formula I-3B, wherein the molar ratio of oxalic acid to the compound represented by formula I-3B is 1:

1.

4. A crystal form, which is the crystal form A of the compound shown in formula I-3B, the crystal form B of the compound shown in formula I-3B, the crystal form of the hydrochloride of the compound shown in formula I-3B, the crystal form of the phosphate of the compound shown in formula I-3B, the crystal form of the fumaric acid complex of the compound shown in formula I-3B, the crystal form of the L-tartrate of the compound shown in formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in formula I-3B, the crystal form of the L-malate of the compound shown in formula I-3B, the crystal form A of the edisylate of the compound shown in formula I-3B, the crystal form B of the edisylate of the compound shown in formula I-3B, the crystal form C of the edisylate of the compound shown in formula I-3B, the crystal form of the methanesulfonate of the compound shown in formula I-3B, the crystal form of the benzenesulfonate of the compound shown in formula I-3B, or the crystal form of the oxalate of the compound shown in formula I-3B; in, The structure of the compound shown in formula I-3B is: The crystalline form A of the compound represented by the formula I-3B has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 18.6±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2° and 14.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the hydrochloride of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2° and 11.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the phosphate of the compound represented by the formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2° and 11.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2° and 22.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2° and 23.3±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak at 6.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2° and 22.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 5.3±0.2° and 18.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; The crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2° and 23.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; The crystalline form of the methanesulfonate of the compound represented by the formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2° and 21.8±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2° and 21.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the oxalate salt of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2° and 16.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

5. The crystal form according to claim 4, characterized in that It meets one or more of the following conditions: (1) The crystalline form A of the compound represented by the formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 23.1±0.2°, 17.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2°; For example, the crystalline form A of the compound represented by the formula I-3B has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 18.6±0.2° and 11.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For another example, the crystalline form A of the compound represented by the formula I-3B has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 23.1±0.2°, 18.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (2) The X-ray powder diffraction pattern of the crystalline form B of the compound represented by the formula I-3B using Cu-Kα radiation and expressed in 2θ angles also has diffraction peaks at one or more of the following positions: 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2°; For example, the crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2° and 19.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (3) In the crystalline form of the hydrochloride of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to hydrochloric acid is 1:0.9; Alternatively, the crystalline form of the hydrochloride of the compound represented by formula I-3B is a crystalline form of the hydrochloride acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, hydrochloric acid and acetone is 1:0.9:0.9; (4) The crystalline form of the hydrochloride of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2°; For example, the crystalline form of the hydrochloride of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2° and 20.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For another example, the crystalline form of the hydrochloride of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2°, 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (5) In the crystal form of the phosphate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to phosphoric acid is 1:0.9; Alternatively, the crystal form of the phosphate of the compound of formula I-3B is a crystal form of phosphate acetone solvate of the compound of formula I-3B, wherein the molar ratio of the compound of formula I-3B, phosphoric acid and acetone is 1:0.9:0.05; (6) The phosphate of the compound of formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at one or more of the following locations: 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2° and 10.2±0.2°; For example, the crystalline form of the phosphate of the compound represented by the formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2° and 19.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For example, the phosphate of the compound of formula I-3B has an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2°. and there are diffraction peaks at 10.2±0.2°; (7) The crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2°; For example, the crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2° and 26.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (8) The crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2°; For example, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2° and 18.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2°, 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (9) The crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2°; For example, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2° and 20.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (10) The crystalline form of the L-malate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2°; For example, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2° and 17.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (11) In the crystalline form A of the ethanedisulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to ethanedisulfonic acid is 1:0.5; Alternatively, the crystalline form A of the edisulphonate of the compound represented by formula I-3B is an isopropanol solvent of the edisulphonate of the compound represented by formula I-3B The crystalline form of the compound, wherein the molar ratio of the compound represented by formula I-3B, ethanedisulfonic acid and isopropanol is 1:0.5:0.5; (12) The crystalline form A of the edisylate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2°; For example, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For another example, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (13) The crystalline form B of the edisylate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2°; For example, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2° and 15.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (14) In the crystalline form C of the ethanedisulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to ethanedisulfonic acid is 1:1; Alternatively, the crystalline form C of the edisylate salt of the compound represented by formula I-3B is a crystalline form of edisylate salt of the compound represented by formula I-3B acetone n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, edisylic acid, acetone and n-heptane is 1:1:03:0.03; (15) The crystalline form C of the edisylate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 7.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2°; For example, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2° and 17.3±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2°, 17.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (16) In the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to methanesulfonic acid is 1:1; Alternatively, the crystalline form of the methanesulfonate of the compound represented by formula I-3B is a crystalline form of the methanesulfonate of the compound represented by formula I-3B n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, methanesulfonic acid and n-heptane is 1:1:0.008; (17) The crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2°; For example, the crystalline form of the mesylate salt of the compound represented by the formula I-3B is determined by using Cu-Kα radiation and X-ray powder diffraction expressed in 2θ angles. The radiation pattern has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2°, and 15.6±0.2°; For another example, the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (18) In the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to benzenesulfonic acid is 1:1; Alternatively, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B is a crystalline form of the benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, benzenesulfonic acid and isopropanol is 1:1:0.01; (19) The benzenesulfonate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at one or more of the following locations: 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2°; For example, the crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, and 19.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (20) The crystalline form of the oxalate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and expressed in 2θ angles: 19.2±0.2°, 15.4±0.2°, 23.6±0.2° and 22.4±0.2°; For example, the crystalline form of the oxalate of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2° and 15.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the oxalate of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2°, 15.4±0.2°, 23.6±0.2° and 22.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (21) The crystalline form A of the compound represented by formula I-3B is a crystalline form of an isopropyl acetate solvate of the compound represented by formula I-3B, and the molar ratio of the compound represented by formula I-3B to the isopropyl acetate is 1:0.04; (22) In the crystalline form of the fumaric acid complex of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to fumaric acid is 1:1; Preferably, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is a fumaric acid cocrystal of the compound represented by formula I-3B; (23) In the crystalline form of the L-tartrate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to L-tartaric acid is 1:1; (24) In the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to p-toluenesulfonic acid is 1:1; (25) In the crystalline form of the L-malate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to L-malic acid is 1:1; (26) In the crystalline form B of the edisylate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to edisylic acid is 1:0.5; and (27) In the crystal form of the oxalate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to oxalic acid is 1:

1.

6. The crystal form according to claim 4, characterized in that The crystal form satisfies one or more of the following conditions: (1) The X-ray powder diffraction pattern of the crystalline form A of the compound represented by the formula I-3B using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 1: Table 1 For example, the crystalline form A of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG1 ; (2) The differential scanning calorimetry curve of the crystalline form A of the compound represented by formula I-3B has an endothermic peak starting point at 160.9±3°C, and / or the differential scanning calorimetry curve of the crystalline form A of the compound represented by formula I-3B reaches an endothermic peak at 168.4±3°C; For example, the differential scanning calorimetry curve of Form A of the compound represented by Formula I-3B is substantially as shown in FIG2 ; (3) The thermogravimetric analysis curve of Form A of the compound represented by Formula I-3B shows a weight loss of approximately 0.67% in the temperature range of 14.8±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of Form A of the compound represented by Formula I-3B is substantially as shown in FIG2 ; (4) The X-ray powder diffraction pattern of the crystalline form B of the compound represented by the formula I-3B using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 2: Table 2 For example, the crystal form B of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG4 ; (5) The differential scanning calorimetry curve of the crystalline form B of the compound represented by formula I-3B has an endothermic peak starting point at about 164.2±3°C, and / or the differential scanning calorimetry curve of the crystalline form B of the compound represented by formula I-3B reaches an endothermic peak at about 171.7±3°C; For example, the differential scanning calorimetry curve of Form B of the compound represented by Formula I-3B is substantially as shown in FIG5 ; (6) The thermogravimetric analysis curve of Form B of the compound represented by Formula I-3B shows a weight loss of approximately 1.61% in the temperature range of 26.6±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of Form B of the compound represented by Formula I-3B is substantially as shown in FIG5 ; (7) The crystalline form of the hydrochloride of the compound represented by the formula I-3B has a diffraction peak as shown in Table 3 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 3 For example, the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG7 ; (8) The differential scanning calorimetry curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B reaches endothermic peaks at 122.1±3°C and 199.6±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B is substantially as shown in FIG8 ; (9) The thermogravimetric analysis curve of the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B shows a weight loss of about 13.39% in the temperature range of 17.7±3°C to 100°C±3°C, and a weight loss of about 4.54% in the temperature range of 100±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B is substantially as shown in FIG8 ; (10) The crystal form of the phosphate of the compound represented by Formula I-3B is determined by X-ray powder diffraction using Cu-Kα radiation and 2θ angles. The figure has diffraction peaks as shown in Table 4: Table 4 For example, the crystal form of the phosphate of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG9 ; (11) The differential scanning calorimetry curve of the crystalline form of the phosphate of the compound represented by formula I-3B reaches the peak of the endothermic peak at 158.5±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the phosphate salt of the compound represented by formula I-3B is substantially as shown in FIG10 ; (12) The thermogravimetric analysis curve of the crystalline form of the phosphate of the compound represented by formula I-3B shows a weight loss of about 2.07% in the temperature range of 27.4±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the phosphate of the compound represented by formula I-3B is substantially as shown in FIG. 10 (13) The crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has a diffraction peak as shown in Table 5 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 5 For example, the crystal form of the fumaric acid complex of the compound represented by Formula I-3B is radiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG11 ; (14) The differential scanning calorimetry curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has an endothermic peak starting point at 165.2±3°C, and / or the differential scanning calorimetry curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B reaches an endothermic peak at 167.2±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is substantially as shown in FIG12 ; (15) The thermogravimetric analysis curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B shows a weight loss of about 0.36% in the temperature range of 26.2±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is substantially as shown in FIG12 ; (16) The crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 6 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 6 For example, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG13 ; (17) The differential scanning calorimetry curve of the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has an endothermic peak starting point at 162.4±3°C, and / or the differential scanning calorimetry curve of the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B reaches an endothermic peak at 165.7±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B is substantially as shown in FIG14 ; (18) The thermogravimetric analysis curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B shows a weight loss of about 0.57% in the temperature range of 25.9±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B is substantially as shown in FIG14 ; (19) The crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 7 using Cu-Kα radiation and expressed in 2θ angles: Table 7 For example, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG15 ; (20) The differential scanning calorimetry curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B reaches the peak of the endothermic peak at 278.9±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B is shown in FIG16 ; (21) The thermogravimetric analysis curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B shows a weight loss of about 0.89% in the temperature range of 25.9±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B is shown in FIG16 ; (22) The crystalline form of the L-malate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 8 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 8 For example, the crystalline form of the L-malate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG17 ; (23) The differential scanning calorimetry curve of the crystalline form of the L-malate salt of the compound represented by the formula I-3B has an endothermic peak starting point at 120.4±3°C, and / or, the differential scanning calorimetry curve of the crystalline form of the L-malate salt of the compound represented by the formula I-3B reaches endothermic peaks at 128.1±3°C and 213.6±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B is substantially as shown in FIG18 ; (24) The thermogravimetric analysis curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B shows a weight loss of approximately 1.31% in the temperature range of 27.5±3°C to 100°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B is substantially as shown in FIG18 ; (25) The crystalline form A of the edisylate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 9 using Cu-Kα radiation and expressed in 2θ angles: Table 9 For example, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG19 ; (26) The differential scanning calorimetry curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B reaches the peak values ​​of the endothermic peaks at 162.8±3°C and 239.7±3°C, and reaches the peak value of the exothermic peak at 198.8±3°C; For example, the differential scanning calorimetry curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B is substantially as shown in FIG20 ; (27) The thermogravimetric analysis curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 9.08% in the temperature range of 25.2±3°C to 170°C±3°C; For example, the thermogravimetric analysis curve of Form A of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG20 ; (28) The crystalline form B of the edisylate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 10 using Cu-Kα radiation and expressed in 2θ angles: Table 10 For example, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG21 ; (29) The differential scanning calorimetry curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B has an endothermic peak starting point at 235.8±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B reaches an endothermic peak at 242.4±3°C; For example, the differential scanning calorimetry curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B is substantially as shown in FIG22 ; (30) The thermogravimetric analysis curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 1.84% in the temperature range of 28.4±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of Form B of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG22 ; (31) The crystalline form C of the edisylate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 11 using Cu-Kα radiation and expressed in 2θ angles: Table 11 For example, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG23 ; (32) The differential scanning calorimetry curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B reaches endothermic peaks at 109.5±3°C and 243.6±3°C; For example, the differential scanning calorimetry curve of Form C of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG24 ; (33) The thermogravimetric analysis curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 7.28% in the temperature range of 28.6±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of Form C of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG24 ; (34) The crystalline form of the methanesulfonate of the compound represented by the formula I-3B has a diffraction peak shown in Table 12 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 12 For example, the crystalline form of the mesylate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG25 ; (35) The differential scanning calorimetry curve of the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has an endothermic peak starting point at 116.3±3°C, and / or the differential scanning calorimetry curve of the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B reaches an endothermic peak at 124.3±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the mesylate salt of the compound represented by Formula I-3B is substantially as shown in FIG26 ; (36) The thermogravimetric analysis curve of the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B shows a weight loss of about 4.53% in the temperature range of 28.4±3°C to 80°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the mesylate salt of the compound represented by Formula I-3B is substantially as shown in FIG26 ; (37) The crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 13 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 13 For example, the benzenesulfonate salt of the compound represented by Formula I-3B is radiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG27 ; (38) The differential scanning calorimetry curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B reaches the peak of the endothermic peak at 254.1±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG28 ; (39) The thermogravimetric analysis curve of the benzenesulfonate salt of the compound represented by Formula I-3B shows a weight loss of about 1.32% in the temperature range of 28.4±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG28 ; (40) The crystalline form of the oxalate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 14 using Cu-Kα radiation and expressed in 2θ angles: Table 14 For example, the crystalline form of the oxalate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG29 ; (41) The differential scanning calorimetry curve of the crystalline form of the oxalate salt of the compound represented by formula I-3B reaches endothermic peaks at 129.7±3°C and 198.2±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B is substantially as shown in FIG30 ; and (42) The thermogravimetric analysis curve of the crystalline form of the oxalate salt of the compound represented by the formula I-3B shows a weight loss of about 2.27% in the temperature range of 28.4±3°C to 100°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B is substantially as shown in FIG. 30 .

7. The crystal form according to claim 4, characterized in that The crystalline form of the fumaric acid complex of the compound represented by formula I-3B has the following unit cell parameters: orthorhombic system, space group P212121; α=90°, β=90°, γ=90°, The number of asymmetric units in the unit cell is Z = 4, and the crystal density is 1.451 mg / m 3 .

8. A method for preparing the crystal form according to any one of claims 4 to 6, characterized in that: It is either method one or method two: Method 1: The preparation method comprises the following steps: crystallizing a mixture of the compound represented by formula I-3B and a solution to obtain a crystalline form of the compound represented by formula I-3B or a solvate thereof; In method 1, when the crystalline form A of the compound represented by formula I-3B is obtained, the solvent is isopropyl acetate; When the crystalline form B of the compound represented by formula I-3B is obtained, the solvent is one or more of methanol, water, acetonitrile and methyl tert-butyl ether; Method 2: The preparation method comprises the following steps: crystallizing a mixture of the compound represented by formula I-3B, an acid and a solvent; In method 2, when the crystalline form of the hydrochloride salt of the compound represented by formula I-3B is obtained, the acid is hydrochloric acid and the solvent is acetone; When the crystalline form of the phosphate of the compound represented by formula I-3B is obtained, the acid is phosphoric acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is obtained, the acid is fumaric acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of L-tartrate of the compound represented by formula I-3B is obtained, the acid is tartaric acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B is obtained, the acid is p-toluenesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystal form of L-malate of the compound represented by formula I-3B is obtained, the acid is malic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form A of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropanol; When the crystalline form B of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropyl acetate; When the crystalline form C of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of the mesylate salt of the compound represented by formula I-3B is obtained, the acid is methanesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of benzenesulfonate of the compound represented by formula I-3B is obtained, the acid is benzenesulfonic acid and the solvent is isopropanol; When the crystalline form of the oxalate of the compound represented by formula I-3B is obtained, the acid is oxalic acid, and the solvent is a mixed solution of acetone and n-heptane; Preferably, the preparation method meets one or more of the following conditions: (1) In the method for preparing the crystalline form of the compound represented by formula I-3B, when the crystalline form B of the compound represented by formula I-3B is obtained, the solvent is a mixed solution of methanol and water or a mixed solution of acetonitrile and methyl tert-butyl ether, preferably a mixed solution of methanol and water with a volume ratio of methanol to water of 1:5; Alternatively, in the method for preparing the crystalline form of the compound shown in Formula I-3B, when the crystalline form A of the compound shown in Formula I-3B is obtained, the crystallization is to cool the mixture of isopropyl acetate and the compound shown in Formula I-3B to room temperature and dry to obtain the crystalline form A of the compound shown in Formula I-3B; (2) In the method for preparing the crystalline form of the compound represented by formula I-3B, when the crystalline form B of the compound represented by formula I-3B is obtained, the crystallization is to crystallize the compound represented by formula I-3B and a mixture of methanol and water at 50° C., and dry to obtain the crystalline form B of the compound represented by formula I-3B; (3) In the preparation method, when the solvent is a mixed solution of acetone and n-heptane, the volume ratio of acetone to n-heptane is 1:1; (4) In the preparation method, the molar ratio of the compound represented by formula I-3B to the acid is 1:1; and (5) The preparation method comprises the following steps: suspending the compound represented by formula I-3B, an acid and a solvent to obtain a mixture, and crystallizing to obtain a crystalline form of a pharmaceutically acceptable salt of the compound represented by formula I-3B; Preferably, in the preparation method, when the obtained product is a crystalline form of hydrochloride of the compound of formula I-3B, a crystalline form of L-malate of the compound of formula I-3B, a crystalline form B of edisylate of the compound of formula I-3B, a crystalline form C of edisylate of the compound of formula I-3B, a crystalline form of methanesulfonate of the compound of formula I-3B or a crystalline form of benzenesulfonate of the compound of formula I-3B, the crystallization comprises the following steps: subjecting the mixture of the compound of formula I-3B, acid and solvent to temperature cycling and drying; Alternatively, in the preparation method, when the crystal form of the phosphate of the compound shown in Formula I-3B, the crystal form of the fumaric acid complex of the compound shown in Formula I-3B, the crystal form of the L-tartrate of the compound shown in Formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in Formula I-3B, the crystal form A of the ethanedisulfonate of the compound shown in Formula I-3B, or the crystal form of the oxalate of the compound shown in Formula I-3B is obtained, the crystallization comprises the following steps: drying the mixture of the compound shown in Formula I-3B, acid and solvent.

9. A pharmaceutical composition, wherein the pharmaceutical composition is any of the following: Solution 1: The pharmaceutical composition comprises a pharmaceutically acceptable salt or a solvate thereof of the heterocyclic compound according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier; Option 2: The pharmaceutical composition comprises a substance X and a pharmaceutically acceptable carrier, wherein the substance X is a crystalline form A of the compound shown in formula I-3B according to any one of claims 4 to 7, a crystalline form B of the compound shown in formula I-3B, a crystalline form of the hydrochloride of the compound shown in formula I-3B, a crystalline form of the phosphate of the compound shown in formula I-3B, a crystalline form of the fumaric acid complex of the compound shown in formula I-3B, a crystalline form of the L-tartrate of the compound shown in formula I-3B, a crystalline form of the p-toluenesulfonate of the compound shown in formula I-3B, a crystalline form of the L-malate of the compound shown in formula I-3B, a crystalline form A of the edisylate of the compound shown in formula I-3B, a crystalline form B of the edisylate of the compound shown in formula I-3B, a crystalline form C of the edisylate of the compound shown in formula I-3B, a crystalline form of the methanesulfonate of the compound shown in formula I-3B, a crystalline form of the benzenesulfonate of the compound shown in formula I-3B, or a crystalline form of the oxalate of the compound shown in formula I-3B.

10. A use of a substance, characterized in that: The substance is a pharmaceutically acceptable salt of a heterocyclic compound according to any one of claims 1 to 3 or a solvate thereof, a pharmaceutical composition according to claim 9 or a substance X; The substance X is the crystal form A of the compound of formula I-3B according to any one of claims 4 to 7, the crystal form B of the compound of formula I-3B, the crystal form of the hydrochloride of the compound of formula I-3B, the crystal form of the phosphate of the compound of formula I-3B, the crystal form of the fumaric acid complex of the compound of formula I-3B, the crystal form of the L-tartrate of the compound of formula I-3B, the crystal form of the p-toluenesulfonate of the compound of formula I-3B, the crystal form of the L-malate of the compound of formula I-3B, the crystal form A of the edisylate of the compound of formula I-3B, the crystal form B of the edisylate of the compound of formula I-3B, the crystal form C of the edisylate of the compound of formula I-3B, the crystal form of the methanesulfonate of the compound of formula I-3B, the crystal form of the benzenesulfonate of the compound of formula I-3B, or the crystal form of the oxalate of the compound of formula I-3B; The application includes: preparing a 15-PGDH inhibitor, and / or preparing a medicine, a pharmaceutical composition or a preparation for preventing and / or treating a disease related to 15-PGDH.

11. Use of the substance according to claim 10, characterized in that The 15-PGDH-related disease is one, two or more of fibrotic disease, inflammatory disease, cardiovascular disease, trauma, autoimmune disease, graft-versus-host disease, hair growth, osteoporosis, ear disease, eye disease, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstruction, tissue damage, cervical disease or kidney disease; preferably one or more of fibrosis, inflammatory disease or tissue damage; Preferably, the 15-PGDH-related disease further satisfies one or more of the following conditions: (1) The fibrotic disease is one or more of pulmonary fibrosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, scleroderma or myelofibrosis, preferably pulmonary fibrosis and / or liver fibrosis, such as pulmonary fibrosis; for example, the pulmonary fibrosis may be idiopathic pulmonary fibrosis; (2) The inflammatory disease is one or more of chronic obstructive pulmonary disease, acute lung injury, sepsis, asthma and exacerbation of lung disease, inflammatory bowel disease, peptic ulcer, autoinflammatory disease, vasculitis syndrome, acute liver injury, acute kidney injury, non-alcoholic fatty liver disease, atopic dermatitis, psoriasis, interstitial cystitis or prostatitis syndrome, preferably inflammatory bowel disease; for example, the inflammatory bowel disease may be ulcerative colitis and / or Crohn's disease; the peptic ulcer may be an NSAID-induced ulcer; the autoinflammatory disease may be Behcet's disease; the prostatitis syndrome may be chronic prostatitis and / or chronic pelvic pain syndrome; (3) The cardiovascular disease is pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, stroke or One or more peripheral circulatory disorders; (4) The trauma is one or more of diabetic ulcer, burn, pressure ulcer, acute mucosal injury, including Stevens-Johnson syndrome, mucosal injury, injury related to anticancer chemotherapy, antimetabolites, cellular or humoral immunotherapy or radiation-related injury; for example, the anticancer chemotherapy may be one or more of alkylating agents, DNA synthesis inhibitors or DNA gyrase inhibitors; (5) The autoimmune disease is multiple sclerosis and / or rheumatoid arthritis; (6) The ear disease is one or more of hearing loss, tinnitus, vertigo or imbalance; (7) The eye disease is glaucoma and / or dry eye; (8) The neurogenesis and neuronal cell death are one or more of a psychiatric neurological disease, a neuropathy, a neurotoxic disease, a neuropathic pain, or a neurodegenerative disease; (9) The tissue damage is liver damage and / or muscle damage; the muscle damage is preferably muscle atrophy and / or muscular dystrophy; and (10) The renal disease is chronic renal disease and / or renal failure; Further preferably, the 15-PGDH-related disease is idiopathic pulmonary fibrosis, liver regeneration, liver injury or inflammatory bowel disease.

12. A use of a substance, characterized in that: The substance is a pharmaceutically acceptable salt of a heterocyclic compound according to any one of claims 1 to 3 or a solvate thereof, a pharmaceutical composition according to claim 9 or a substance X; The substance X is the crystal form A of the compound of formula I-3B according to any one of claims 4 to 7, the crystal form B of the compound of formula I-3B, the crystal form of the hydrochloride of the compound of formula I-3B, the crystal form of the phosphate of the compound of formula I-3B, the crystal form of the fumaric acid complex of the compound of formula I-3B, the crystal form of the L-tartrate of the compound of formula I-3B, the crystal form of the p-toluenesulfonate of the compound of formula I-3B, the crystal form of the L-malate of the compound of formula I-3B, the crystal form A of the edisylate of the compound of formula I-3B, the crystal form B of the edisylate of the compound of formula I-3B, the crystal form C of the edisylate of the compound of formula I-3B, the crystal form of the methanesulfonate of the compound of formula I-3B, the crystal form of the benzenesulfonate of the compound of formula I-3B, or the crystal form of the oxalate of the compound of formula I-3B; The application is to prepare drugs for preventing or treating the following diseases; the diseases are one or more of fibrotic diseases, inflammatory diseases or tissue damage; For example, the fibrotic disease, the inflammatory disease and the tissue damage are all as described in claim 11.

Citation Information

Patent Citations

  • 15-PGDH inhibitor and application

    CN116135856A

  • 15-PGDH inhibitor

    CN113226310A

  • PGDH inhibitors and methods of making and using

    CN115335043A

  • 15-PGDH inhibitors

    WO2020160151A1

  • CN202310513152A